BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: American Thoracic Society; European Respiratory Society. American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med. 2003;168:818-900. [PMID: 14522813 DOI: 10.1164/rccm.168.7.818] [Cited by in Crossref: 612] [Cited by in F6Publishing: 478] [Article Influence: 43.7] [Reference Citation Analysis]
Number Citing Articles
1 Greulich T. Alpha-1-Antitrypsin Deficiency: Disease Management and Learning from Studies. COPD 2017;14:S8-S11. [PMID: 28306355 DOI: 10.1080/15412555.2017.1286166] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
2 de Serres FJ, Blanco I, Fernández-Bustillo E. Estimating the risk for alpha-1 antitrypsin deficiency among COPD patients: evidence supporting targeted screening. COPD. 2006;3:133-139. [PMID: 17240615 DOI: 10.1080/15412550600829257] [Cited by in Crossref: 32] [Cited by in F6Publishing: 22] [Article Influence: 2.3] [Reference Citation Analysis]
3 Joly P, Guillaud O, Hervieu V, Francina A, Mornex JF, Chapuis-Cellier C. Clinical heterogeneity and potential high pathogenicity of the Mmalton Alpha 1 antitrypsin allele at the homozygous, compound heterozygous and heterozygous states. Orphanet J Rare Dis 2015;10:130. [PMID: 26446624 DOI: 10.1186/s13023-015-0350-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
4 Balbi B, Ferrarotti I, Miravitlles M. Efficacy of augmentation therapy for emphysema associated with α 1 -antitrypsin deficiency: enough is enough. Eur Respir J 2015;47:35-8. [DOI: 10.1183/13993003.01145-2015] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
5 Craig TJ, Henao MP. Advances in managing COPD related to α1 -antitrypsin deficiency: An under-recognized genetic disorder. Allergy 2018;73:2110-21. [PMID: 29984428 DOI: 10.1111/all.13558] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
6 Gulack BC, Mulvihill MS, Ganapathi AM, Speicher PJ, Chery G, Snyder LD, Davis RD, Hartwig MG. Survival after lung transplantation in recipients with alpha-1-antitrypsin deficiency compared to other forms of chronic obstructive pulmonary disease: a national cohort study. Transpl Int 2018;31:45-55. [PMID: 28833662 DOI: 10.1111/tri.13038] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
7 Cardoso FS, Karvellas CJ. Respiratory Complications Before and After Liver Transplant. J Intensive Care Med 2019;34:355-63. [PMID: 29886790 DOI: 10.1177/0885066618781526] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
8 Ferrarotti I, Corsico AG, Stolk J, Ottaviani S, Fumagalli M, Janciauskiene S, Iadarola P. Advances in Identifying Urine/Serum Biomarkers in Alpha-1 Antitrypsin Deficiency for More Personalized Future Treatment Strategies. COPD 2017;14:56-65. [PMID: 27827549 DOI: 10.1080/15412555.2016.1241760] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
9 Franciosi AN, Hobbs BD, McElvaney OJ, Molloy K, Hersh C, Clarke L, Gunaratnam C, Silverman EK, Carroll TP, McElvaney NG. Clarifying the Risk of Lung Disease in SZ Alpha-1 Antitrypsin Deficiency. Am J Respir Crit Care Med 2020;202:73-82. [PMID: 32197047 DOI: 10.1164/rccm.202002-0262OC] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 10.0] [Reference Citation Analysis]
10 Stockley RA, Miravitlles M, Vogelmeier C; Alpha One International Registry (A.I.R.). Augmentation therapy for alpha-1 antitrypsin deficiency: towards a personalised approach. Orphanet J Rare Dis 2013;8:149. [PMID: 24063809 DOI: 10.1186/1750-1172-8-149] [Cited by in Crossref: 52] [Cited by in F6Publishing: 45] [Article Influence: 6.5] [Reference Citation Analysis]
11 Tanash HA, Nystedt-düzakin M, Montero LC, Sveger T, Piitulainen E. The Swedish α 1 -Antitrypsin Screening Study: Health Status and Lung and Liver Function at Age 34. Annals ATS 2015;12:807-12. [DOI: 10.1513/annalsats.201410-452oc] [Cited by in Crossref: 19] [Cited by in F6Publishing: 7] [Article Influence: 3.2] [Reference Citation Analysis]
12 Jardim JR, Casas-Maldonado F, Fernandes FLA, Castellano MVCO, Torres-Durán M, Miravitlles M. Update on and future perspectives for the diagnosis of alpha-1 antitrypsin deficiency in Brazil. J Bras Pneumol 2021;47:e20200380. [PMID: 34076174 DOI: 10.36416/1806-3756/e20200380] [Reference Citation Analysis]
13 Klitzman R. The impact of social contexts in testing for alpha-1 antitrypsin deficiency: the roles of physicians and others. Genet Test Mol Biomarkers 2009;13:269-76. [PMID: 19371228 DOI: 10.1089/gtmb.2008.0106] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
14 Soy D, de la Roza C, Lara B, Esquinas C, Torres A, Miravitlles M. Alpha-1-antitrypsin deficiency: optimal therapeutic regimen based on population pharmacokinetics. Thorax 2006;61:1059-64. [PMID: 16928711 DOI: 10.1136/thx.2005.057943] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 2.2] [Reference Citation Analysis]
15 Pervakova MY, Emanuel VL, Titova ON, Lapin SV, Mazurov VI, Belyaeva IB, Chudinov AL, Blinova TV, Surkova EA. The Diagnostic Value of Alpha-1-Antitrypsin Phenotype in Patients with Granulomatosis with Polyangiitis. Int J Rheumatol 2016;2016:7831410. [PMID: 27127514 DOI: 10.1155/2016/7831410] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
16 Ljujic M, Nikolic A, Divac A, Djordjevic V, Radojkovic D. Screening of alpha-1-antitrypsin gene by denaturing gradient gel electrophoresis (DGGE). Journal of Biochemical and Biophysical Methods 2006;68:167-73. [DOI: 10.1016/j.jbbm.2006.05.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
17 Abusriwil H, Stockley RA. Alpha-1-antitrypsin replacement therapy: current status. Curr Opin Pulm Med. 2006;12:125-131. [PMID: 16456382 DOI: 10.1097/01.mcp.0000208452.57854.c6] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 1.9] [Reference Citation Analysis]
18 Henao MP, Craig TJ. Recent advances in understanding and treating COPD related to α1-antitrypsin deficiency. Expert Rev Respir Med 2016;10:1281-94. [PMID: 27771979 DOI: 10.1080/17476348.2016.1249851] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
19 Casas F, Blanco I, Martínez MT, Bustamante A, Miravitlles M, Cadenas S, Hernández JM, Lázaro L, Rodríguez E, Rodríguez-frías F, Torres M, Lara B. Actualización sobre indicaciones de búsqueda activa de casos y tratamiento con alfa-1 antitripsina por vía intravenosa en pacientes con enfermedad pulmonar obstructiva crónica asociada a déficit de alfa-1 antitripsina. Archivos de Bronconeumología 2015;51:185-92. [DOI: 10.1016/j.arbres.2014.05.008] [Cited by in Crossref: 44] [Cited by in F6Publishing: 33] [Article Influence: 7.3] [Reference Citation Analysis]
20 Lachaux A, Dumortier J. [Hepatic involvement in hereditary alpha-1-antitrypsin deficiency]. Rev Mal Respir 2014;31:357-64. [PMID: 24750955 DOI: 10.1016/j.rmr.2013.10.651] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
21 Serrano-Mollar A. [Alveolar epithelial cell injury as an etiopathogenic factor in pulmonary fibrosis]. Arch Bronconeumol 2012;48 Suppl 2:2-6. [PMID: 23116901 DOI: 10.1016/S0300-2896(12)70044-3] [Cited by in Crossref: 23] [Article Influence: 2.9] [Reference Citation Analysis]
22 Silva D, Oliveira MJ, Guimarães M, Lima R, Gomes S, Seixas S. Alpha-1-antitrypsin (SERPINA1) mutation spectrum: Three novel variants and haplotype characterization of rare deficiency alleles identified in Portugal. Respiratory Medicine 2016;116:8-18. [DOI: 10.1016/j.rmed.2016.05.002] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 5.0] [Reference Citation Analysis]
23 Teschler H. Long-term experience in the treatment of α1-antitrypsin deficiency: 25 years of augmentation therapy. Eur Respir Rev 2015;24:46-51. [PMID: 25726554 DOI: 10.1183/09059180.10010714] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
24 Perrin JT, Kennedy CC. 48-Year-Old Man With Dyspnea on Exertion. Mayo Clin Proc 2016;91:509-13. [PMID: 26803352 DOI: 10.1016/j.mayocp.2015.08.025] [Reference Citation Analysis]
25 Doshi SD, Wood L, Abt PL, Olthoff KM, Shaked A, Goldberg DS, Bittermann T. Outcomes of Living-donor Liver Transplantation Using Grafts Heterozygous for α-1 Antitrypsin Gene Mutations. Transplantation 2019;103:1175-80. [DOI: 10.1097/tp.0000000000002493] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
26 Kemmer N, Kaiser T, Zacharias V, Neff G. Alpha-1-Antitrypsin Deficiency: Outcomes After Liver Transplantation. Transplantation Proceedings 2008;40:1492-4. [DOI: 10.1016/j.transproceed.2008.02.075] [Cited by in Crossref: 57] [Cited by in F6Publishing: 28] [Article Influence: 4.4] [Reference Citation Analysis]
27 Chiuchiolo MJ, Kaminsky SM, Sondhi D, Hackett NR, Rosenberg JB, Frenk EZ, Hwang Y, Van de Graaf BG, Hutt JA, Wang G, Benson J, Crystal RG. Intrapleural Administration of an AAVrh.10 Vector Coding for Human α1-Antitrypsin for the Treatment of α1-Antitrypsin Deficiency. Human Gene Therapy Clinical Development 2013;24:161-73. [DOI: 10.1089/humc.2013.168] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 4.3] [Reference Citation Analysis]
28 Blanco I, Lipsker D, Lara B, Janciauskiene S. Neutrophilic panniculitis associated with alpha-1-antitrypsin deficiency: an update. Br J Dermatol 2016;174:753-62. [DOI: 10.1111/bjd.14309] [Cited by in Crossref: 30] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
29 McElvaney NG, Burdon J, Holmes M, Glanville A, Wark PA, Thompson PJ, Hernandez P, Chlumsky J, Teschler H, Ficker JH, Seersholm N, Altraja A, Mäkitaro R, Chorostowska-Wynimko J, Sanak M, Stoicescu PI, Piitulainen E, Vit O, Wencker M, Tortorici MA, Fries M, Edelman JM, Chapman KR; RAPID Extension Trial Group. Long-term efficacy and safety of α1 proteinase inhibitor treatment for emphysema caused by severe α1 antitrypsin deficiency: an open-label extension trial (RAPID-OLE). Lancet Respir Med 2017;5:51-60. [PMID: 27916480 DOI: 10.1016/S2213-2600(16)30430-1] [Cited by in Crossref: 80] [Cited by in F6Publishing: 50] [Article Influence: 16.0] [Reference Citation Analysis]
30 Martin P, DiMartini A, Feng S, Brown R, Fallon M. Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Hepatology. 2014;59:1144-1165. [PMID: 24716201 DOI: 10.1002/hep.26972] [Cited by in Crossref: 429] [Cited by in F6Publishing: 317] [Article Influence: 61.3] [Reference Citation Analysis]
31 Dauriat G, Mal H, Jebrak G, Brugière O, Castier Y, Camuset J, Marceau A, Taillé C, Lesèche G, Fournier M. Functional results of unilateral lung volume reduction surgery in alpha1-antitrypsin deficient patients. Int J Chron Obstruct Pulmon Dis 2006;1:201-6. [PMID: 18046897 DOI: 10.2147/copd.2006.1.2.201] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
32 Bernspång E, Sveger T, Piitulainen E. Respiratory symptoms and lung function in 30-year-old individuals with alpha-1-antitrypsin deficiency. Respiratory Medicine 2007;101:1971-6. [DOI: 10.1016/j.rmed.2007.04.003] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 2.1] [Reference Citation Analysis]
33 Norton B, Denson J, Briggs C, Bowles M, Stell D, Aroori S. Delayed diagnosis of alpha-1-antitrypsin deficiency following post-hepatectomy liver failure: A case report. World J Gastroenterol 2016; 22(11): 3289-3295 [PMID: 27004008 DOI: 10.3748/wjg.v22.i11.3289] [Cited by in CrossRef: 3] [Article Influence: 0.6] [Reference Citation Analysis]
34 Hernández Pérez JM, Blanco I, Jesús Sánchez Medina A, Díaz Hernández L, Antonio Pérez Pérez J. Serum Levels of Glutamate-Pyruvate Transaminase, Glutamate-Oxaloacetate Transaminase and Gamma-Glutamyl Transferase in 1494 Patients with Various Genotypes for the Alpha-1 Antitrypsin Gene. J Clin Med 2020;9:E3923. [PMID: 33287251 DOI: 10.3390/jcm9123923] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
35 Kalfopoulos M, Wetmore K, ElMallah MK. Pathophysiology of Alpha-1 Antitrypsin Lung Disease. Methods Mol Biol. 2017;1639:9-19. [PMID: 28752442 DOI: 10.1007/978-1-4939-7163-3_2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
36 Tran HN, Siu S, Iribarren C, Udaltsova N, Klatsky AL. Ethnicity and risk of hospitalization for asthma and chronic obstructive pulmonary disease. Ann Epidemiol 2011;21:615-22. [PMID: 21414801 DOI: 10.1016/j.annepidem.2010.10.015] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
37 Boerema DJ, An B, Gandhi RP, Papineau R, Regnier E, Wilder A, Molitor A, Tang AP, Kee SM. Biochemical comparison of four commercially available human α1-proteinase inhibitors for treatment of α1-antitrypsin deficiency. Biologicals 2017;50:63-72. [PMID: 28882403 DOI: 10.1016/j.biologicals.2017.08.010] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
38 Foray N, Stone T, White P. Alpha1-antitrypsin Disease, Treatment and Role for Lung Volume Reduction Surgery. Thorac Surg Clin 2021;31:139-60. [PMID: 33926668 DOI: 10.1016/j.thorsurg.2021.02.002] [Reference Citation Analysis]
39 Mostafavi B, Diaz S, Piitulainen E, Stoel BC, Wollmer P, Tanash HA. Lung function and CT lung densitometry in 37- to 39-year-old individuals with alpha-1-antitrypsin deficiency. Int J Chron Obstruct Pulmon Dis 2018;13:3689-98. [PMID: 30510411 DOI: 10.2147/COPD.S167497] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
40 Chan ED, Pott GB, Silkoff PE, Ralston AH, Bryan CL, Shapiro L. Alpha-1-antitrypsin inhibits nitric oxide production. J Leukoc Biol 2012;92:1251-60. [PMID: 22975343 DOI: 10.1189/jlb.0212071] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
41 Stoller JK, Aboussouan LS. A review of α1-antitrypsin deficiency. Am J Respir Crit Care Med. 2012;185:246-259. [PMID: 21960536 DOI: 10.1164/rccm.201108-1428CI] [Cited by in Crossref: 253] [Cited by in F6Publishing: 110] [Article Influence: 25.3] [Reference Citation Analysis]
42 Sharp RR, Yarborough M, Walsh JW; Ethical, Legal, Social Issues Working Group of the Alpha-1 Foundation. Responsible patient advocacy: perspectives from the Alpha-1 Foundation. Am J Med Genet A 2008;146A:2845-50. [PMID: 18932220 DOI: 10.1002/ajmg.a.32558] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
43 Takei N, Suzuki M, Makita H, Konno S, Shimizu K, Kimura H, Kimura H, Nishimura M. Serum Alpha-1 Antitrypsin Levels and the Clinical Course of Chronic Obstructive Pulmonary Disease. Int J Chron Obstruct Pulmon Dis 2019;14:2885-93. [PMID: 31849461 DOI: 10.2147/COPD.S225365] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
44 Belmonte I, Barrecheguren M, López-Martínez RM, Esquinas C, Rodríguez E, Miravitlles M, Rodríguez-Frías F. Application of a diagnostic algorithm for the rare deficient variant Mmalton of alpha-1-antitrypsin deficiency: a new approach. Int J Chron Obstruct Pulmon Dis 2016;11:2535-41. [PMID: 27877030 DOI: 10.2147/COPD.S115940] [Cited by in Crossref: 9] [Article Influence: 1.8] [Reference Citation Analysis]
45 Roche D, Mesner A, Al Nakib M, Leonard F, Beaune P. Automated Determination of Serum α1-Antitrypsin by Antitryptic Activity Measurement. Clinical Chemistry 2009;55:513-8. [DOI: 10.1373/clinchem.2008.117002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
46 de Serres FJ, Blanco I, Fernández-bustillo E. Health implications of α1-antitrypsin deficiency in Sub-Sahara African countries and their emigrants in Europe and the New World. Genet Med 2005;7:175-84. [DOI: 10.1097/01.gim.0000156533.06057.89] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
47 Boschetto P, Quintavalle S, Zeni E, Leprotti S, Potena A, Ballerin L, Papi A, Palladini G, Luisetti M, Annovazzi L, Iadarola P, De Rosa E, Fabbri LM, Mapp CE. Association between markers of emphysema and more severe chronic obstructive pulmonary disease. Thorax 2006;61:1037-42. [PMID: 16769715 DOI: 10.1136/thx.2006.058321] [Cited by in Crossref: 112] [Cited by in F6Publishing: 107] [Article Influence: 7.5] [Reference Citation Analysis]
48 Schouten IGM, Mumford RA, Moes DJAR, Hiemstra PS, Stolk J. The Course of AαVal541 as a Proteinase 3 Specific Neo-Epitope after Alpha-1-Antitrypsin Augmentation in Severe Deficient Patients. Int J Mol Sci 2021;22:8031. [PMID: 34360796 DOI: 10.3390/ijms22158031] [Reference Citation Analysis]
49 Kaczor MP, Sanak M, Szczeklik A. Molecular diagnostics of α 1 -antitrypsin deficiency. Expert Opinion on Medical Diagnostics 2007;1:253-65. [DOI: 10.1517/17530059.1.2.253] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
50 Sandström CS, Piitulainen E, Janciauskiene S. Augmentation therapy in emphysema patient with ZZ α-1-antitrypsin deficiency. Respiratory Medicine CME 2008;1:153-7. [DOI: 10.1016/j.rmedc.2008.03.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
51 Tubío-pérez RA, Blanco-pérez M, Ramos-hernández C, Torres-durán M. Descripción de la deficiencia de alfa-1-antitripsina asociada al alelo PI*Q0 Ourém en una niña de 2 años de edad y su estudio familiar. Un caso infrecuente. Archivos de Bronconeumología 2018;54:228-30. [DOI: 10.1016/j.arbres.2017.09.011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
52 Richmond RJ, Zellner KM. ??1-Antitrypsin Deficiency: Incidence and Implications. Dimensions of Critical Care Nursing 2005;24:255-60. [DOI: 10.1097/00003465-200511000-00001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
53 Pérez-Rubio G, Ambrocio-Ortiz E, López-Flores LA, Juárez-Martín AI, Jiménez-Valverde LO, Zoreque-Cabrera S, Galicia-Negrete G, Ramírez-Díaz ME, Cruz-Vicente F, Castillejos-López MJ, Salinas-Lara C, Hernández-Zenteno RJ, Ramírez-Venegas A, Falfán-Valencia R. Heterozygous Genotype rs17580 AT (PiS) in SERPINA1 is Associated with COPD Secondary to Biomass-Burning and Tobacco Smoking: A Case-Control and Populational Study. Int J Chron Obstruct Pulmon Dis 2020;15:1181-90. [PMID: 32547005 DOI: 10.2147/COPD.S247446] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
54 Miravitlles M, Soler-cataluña JJ, Calle M, Molina J, Almagro P, Quintano JA, Riesco JA, Trigueros JA, Piñera P, Simón A, López-campos JL, Soriano JB, Ancochea J. Spanish COPD Guidelines (GesEPOC): Pharmacological Treatment of Stable COPD. Archivos de Bronconeumología (English Edition) 2012;48:247-57. [DOI: 10.1016/j.arbr.2012.05.003] [Cited by in Crossref: 18] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
55 Walsh JW. The Alpha-1 Constellation of Voluntary Health Organizations as a Paradigm for Confronting Rare Diseases. In: Wanner A, Sandhaus RA, editors. Alpha-1 Antitrypsin. Cham: Springer International Publishing; 2016. pp. 157-70. [DOI: 10.1007/978-3-319-23449-6_9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
56 Achatz MI, Hainaut P, Ashton-Prolla P. Highly prevalent TP53 mutation predisposing to many cancers in the Brazilian population: a case for newborn screening? Lancet Oncol 2009;10:920-5. [PMID: 19717094 DOI: 10.1016/S1470-2045(09)70089-0] [Cited by in Crossref: 46] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
57 McElvaney GN, Sandhaus RA, Miravitlles M, Turino GM, Seersholm N, Wencker M, Stockley RA. Clinical considerations in individuals with α1-antitrypsin PI*SZ genotype. Eur Respir J 2020;55:1902410. [PMID: 32165400 DOI: 10.1183/13993003.02410-2019] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 9.0] [Reference Citation Analysis]
58 Petrache I, Hajjar J, Campos M. Safety and efficacy of alpha-1-antitrypsin augmentation therapy in the treatment of patients with alpha-1-antitrypsin deficiency. Biologics 2009;3:193-204. [PMID: 19707408 DOI: 10.2147/btt.2009.3088] [Cited by in Crossref: 2] [Cited by in F6Publishing: 30] [Article Influence: 0.2] [Reference Citation Analysis]
59 Fanos JH, Strange C. ?The Lion, the Witch and the Wardrobe?: Impact on sibs of individuals with AAT deficiency. Am J Med Genet 2004;130A:251-7. [DOI: 10.1002/ajmg.a.30255] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
60 Luisetti M, Ferrarotti I, Corda L, Ottaviani S, Gatta N, Tinelli C, Bruletti G, Bertella E, Balestroni G, Confalonieri M, Seebacher C, Iannacci L, Ferrari S, Salerno FG, Mariani F, Carone M, Balbi B. Italian registry of patients with alpha-1 antitrypsin deficiency: general data and quality of life evaluation. COPD 2015;12 Suppl 1:52-7. [PMID: 25938293 DOI: 10.3109/15412555.2015.1023393] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
61 Aljarallah B, Ali A, Dowaidar M, Settin A. Prevalence of α-1-antitrypsin gene mutations in Saudi Arabia. Saudi J Gastroenterol 2011;17:256-60. [PMID: 21727732 DOI: 10.4103/1319-3767.82580] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
62 Teckman J, Pardee E, Howell RR, Mannino D, Sharp RR, Brantly M, Wanner A, Lamson J; Alpha-1 Foundation Workshop Attendees. Appropriateness of newborn screening for α1-antitrypsin deficiency. J Pediatr Gastroenterol Nutr 2014;58:199-203. [PMID: 24121147 DOI: 10.1097/MPG.0000000000000196] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
63 Holm KE, Mannino DM, Choate R, Sandhaus RA. Genotype is associated with smoking and other key health behaviors among individuals with alpha-1 antitrypsin deficiency-associated lung disease. Respir Med 2018;143:48-55. [PMID: 30261992 DOI: 10.1016/j.rmed.2018.08.016] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
64 Denden S, Lakhdar R, Leban N, Ben Chibani J, Haj Khelil A. Rapid genotyping of alpha 1 antitrypsin deletion mutation (PI*Mmalton) using bi-directional PCR allele-specific amplification. Mol Biotechnol 2010;45:111-5. [PMID: 20108056 DOI: 10.1007/s12033-010-9246-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
65 Murray JD, Willrich MA, Krowka MJ, Bobr A, Murray DL, Halling KC, Graham RP, Snyder MR. Liquid Chromatography-Tandem Mass Spectrometry-Based α1-Antitrypsin (AAT) Testing. Am J Clin Pathol 2021;155:547-52. [PMID: 33083828 DOI: 10.1093/ajcp/aqaa149] [Reference Citation Analysis]
66 Tanash HA, Riise GC, Hansson L, Nilsson PM, Piitulainen E. Survival benefit of lung transplantation in individuals with severe α1-anti-trypsin deficiency (PiZZ) and emphysema. J Heart Lung Transplant 2011;30:1342-7. [PMID: 21821433 DOI: 10.1016/j.healun.2011.07.003] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 3.2] [Reference Citation Analysis]
67 Attaway A, Majumdar U, Sandhaus RA, Nowacki AS, Stoller JK. An analysis of the degree of concordance among international guidelines regarding alpha-1 antitrypsin deficiency. Int J Chron Obstruct Pulmon Dis 2019;14:2089-101. [PMID: 31564856 DOI: 10.2147/COPD.S208591] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
68 Finotti M, Auricchio P, Vitale A, Gringeri E, Cillo U. Liver transplantation for rare liver diseases and rare indications for liver transplant. Transl Gastroenterol Hepatol 2021;6:27. [PMID: 33824931 DOI: 10.21037/tgh-19-282] [Reference Citation Analysis]
69 Tanash HA, Ekström M, Wagner P, Piitulainen E. Cause-specific mortality in individuals with severe alpha 1-antitrypsin deficiency in comparison with the general population in Sweden. Int J Chron Obstruct Pulmon Dis 2016;11:1663-9. [PMID: 27555756 DOI: 10.2147/COPD.S109173] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 3.4] [Reference Citation Analysis]
70 Meira L, Boaventura R, Seixas S, Sucena M. Alpha-1 Antitrypsin Deficiency Detection in a Portuguese Population. COPD 2018;15:4-9. [PMID: 29393705 DOI: 10.1080/15412555.2017.1414779] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
71 Mal H, Guignabert C, Thabut G, d'Ortho MP, Brugière O, Dauriat G, Marrash-chahla R, Rangheard A, Lesèche G, Fournier M. Recurrence of Pulmonary Emphysema in an α-1 Proteinase Inhibitor-deficient Lung Transplant Recipient. Am J Respir Crit Care Med 2004;170:811-4. [DOI: 10.1164/rccm.200312-1726cr] [Cited by in Crossref: 21] [Cited by in F6Publishing: 2] [Article Influence: 1.2] [Reference Citation Analysis]
72 Camelier AA, Winter DH, Jardim JR, Barboza CE, Cukier A, Miravitlles M. [Alpha-1 antitrypsin deficiency: diagnosis and treatment]. J Bras Pneumol 2008;34:514-27. [PMID: 18695797 DOI: 10.1590/s1806-37132008000700012] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
73 López-Campos JL, Carrasco Hernandez L, Caballero Eraso C. Implications of a Change of Paradigm in Alpha1 Antitrypsin Deficiency Augmentation Therapy: From Biochemical to Clinical Efficacy. J Clin Med 2020;9:E2526. [PMID: 32764414 DOI: 10.3390/jcm9082526] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
74 Pujazon MC, Carles P. [Augmentation therapy with alpha-1 antitrypsin: 20 year- follow-up of a deficient patient]. Rev Mal Respir 2008;25:1136-41. [PMID: 19106912 DOI: 10.1016/s0761-8425(08)74986-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
75 Solomon GM, Raju SV, Dransfield MT, Rowe SM. Therapeutic Approaches to Acquired Cystic Fibrosis Transmembrane Conductance Regulator Dysfunction in Chronic Bronchitis. Ann Am Thorac Soc 2016;13 Suppl 2:S169-76. [PMID: 27115953 DOI: 10.1513/AnnalsATS.201509-601KV] [Cited by in F6Publishing: 19] [Reference Citation Analysis]
76 Lace B, Sveger T, Krams A, Cernevska G, Krumina A. Age of SERPINA1 gene PI Z mutation: Swedish and Latvian population analysis. Ann Hum Genet. 2008;72:300-304. [PMID: 18294358 DOI: 10.1111/j.1469-1809.2008.00431.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
77 Pott GB, Beard KS, Bryan CL, Merrick DT, Shapiro L. Alpha-1 antitrypsin reduces severity of pseudomonas pneumonia in mice and inhibits epithelial barrier disruption and pseudomonas invasion of respiratory epithelial cells. Front Public Health 2013;1:19. [PMID: 24350188 DOI: 10.3389/fpubh.2013.00019] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
78 Kelbel T, Morris D, Walker D, Henao MP, Craig T. The Allergist's Role in Detection of Severe Alpha-1 Antitrypsin Deficiency. J Allergy Clin Immunol Pract 2017;5:1302-6. [PMID: 28284783 DOI: 10.1016/j.jaip.2017.01.008] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
79 Bellemare J, Gaudreault N, Valette K, Belmonte I, Nuñez A, Miravitlles M, Maltais F, Bossé Y. The Clinical Utility of Determining the Allelic Background of Mutations Causing Alpha-1 Antitrypsin Deficiency: The Case with the Null Variant Q0(Mattawa)/Q0(Ourém). Chronic Obstr Pulm Dis 2021;8. [PMID: 33150777 DOI: 10.15326/jcopdf.8.1.2020.0168] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
80 Jagger AM, Waudby CA, Irving JA, Christodoulou J, Lomas DA. High-resolution ex vivo NMR spectroscopy of human Z α1-antitrypsin. Nat Commun 2020;11:6371. [PMID: 33311470 DOI: 10.1038/s41467-020-20147-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
81 Gáldiz Iturri JB. Terapia de aumento en la actualidad: con. Archivos de Bronconeumología 2018;54:361-2. [DOI: 10.1016/j.arbres.2017.12.017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
82 Carroll TP, O'Connor CA, Floyd O, McPartlin J, Kelleher DP, O'Brien G, Dimitrov BD, Morris VB, Taggart CC, McElvaney NG. The prevalence of alpha-1 antitrypsin deficiency in Ireland. Respir Res 2011;12:91. [PMID: 21752289 DOI: 10.1186/1465-9921-12-91] [Cited by in Crossref: 54] [Cited by in F6Publishing: 43] [Article Influence: 5.4] [Reference Citation Analysis]
83 Monk R, Graves M, Williams P, Strange C. Inhaled alpha 1-antitrypsin: gauging patient interest in a new treatment. COPD 2013;10:411-5. [PMID: 23537112 DOI: 10.3109/15412555.2012.758698] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
84 Greulich T, Ottaviani S, Bals R, Lepper PM, Vogelmeier C, Luisetti M, Ferrarotti I. Alpha1-antitrypsin deficiency – Diagnostic testing and disease awareness in Germany and Italy. Respiratory Medicine 2013;107:1400-8. [DOI: 10.1016/j.rmed.2013.04.023] [Cited by in Crossref: 59] [Cited by in F6Publishing: 45] [Article Influence: 7.4] [Reference Citation Analysis]
85 Barker AF, Campos MA, Brantly ML, Stocks JM, Sandhaus RA, Lee D, Steinmann K, Lin J, Sorrells S. Bioequivalence of a Liquid Formulation of Alpha1-Proteinase Inhibitor Compared with Prolastin®-C (Lyophilized Alpha1-PI) in Alpha1-Antitrypsin Deficiency. COPD 2017;14:590-6. [PMID: 28985109 DOI: 10.1080/15412555.2017.1376044] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
86 Kueppers F. Clinical presentations of four patients with rare Alpha 1 Antitrypsin variants identified in a single US center. Respir Med Case Rep 2021;32:101345. [PMID: 33552892 DOI: 10.1016/j.rmcr.2021.101345] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
87 Marques PI, Ferreira Z, Martins M, Figueiredo J, Silva DI, Castro P, Morales-Hojas R, Simões-Correia J, Seixas S. SERPINA2 is a novel gene with a divergent function from SERPINA1. PLoS One 2013;8:e66889. [PMID: 23826168 DOI: 10.1371/journal.pone.0066889] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
88 Zorzetto M, Russi E, Senn O, Imboden M, Ferrarotti I, Tinelli C, Campo I, Ottaviani S, Scabini R, von Eckardstein A. SERPINA1 gene variants in individuals from the general population with reduced alpha1-antitrypsin concentrations. Clin Chem. 2008;54:1331-1338. [PMID: 18515255 DOI: 10.1373/clinchem.2007.102798] [Cited by in Crossref: 47] [Cited by in F6Publishing: 41] [Article Influence: 3.6] [Reference Citation Analysis]
89 Marciniuk DD, Hernandez P, Balter M, Bourbeau J, Chapman KR, Ford GT, Lauzon JL, Maltais F, O'Donnell DE, Goodridge D, Strange C, Cave AJ, Curren K, Muthuri S; Canadian Thoracic Society COPD Clinical Assembly Alpha-1 Antitrypsin Deficiency Expert Working Group. Alpha-1 antitrypsin deficiency targeted testing and augmentation therapy: a Canadian Thoracic Society clinical practice guideline. Can Respir J 2012;19:109-16. [PMID: 22536580 DOI: 10.1155/2012/920918] [Cited by in Crossref: 55] [Cited by in F6Publishing: 49] [Article Influence: 6.1] [Reference Citation Analysis]
90 Hersh CP, DeMeo DL, Silverman EK. National Emphysema Treatment Trial state of the art: genetics of emphysema. Proc Am Thorac Soc 2008;5:486-93. [PMID: 18453360 DOI: 10.1513/pats.200706-078ET] [Cited by in Crossref: 21] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
91 Lopes AP, Mineiro MA, Costa F, Gomes J, Santos C, Antunes C, Maia D, Melo R, Canotilho M, Magalhães E, Vicente I, Valente C, Gonçalves BG, Conde B, Guimarães C, Sousa C, Amado J, Brandão ME, Sucena M, Oliveira MJ, Seixas S, Teixeira V, Telo L. Portuguese consensus document for the management of alpha-1-antitrypsin deficiency. Pulmonology 2018;24 Suppl 1:1-21. [PMID: 30473034 DOI: 10.1016/j.pulmoe.2018.09.004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
92 Mitchell EL, Khan Z. Liver Disease in Alpha-1 Antitrypsin Deficiency: Current Approaches and Future Directions. Curr Pathobiol Rep 2017;5:243-52. [PMID: 29399420 DOI: 10.1007/s40139-017-0147-5] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 6.5] [Reference Citation Analysis]
93 Holme J, Dawkins PA, Stockley EK, Parr DG, Stockley RA. Studies of gamma-glutamyl transferase in alpha-1 antitrypsin deficiency. COPD 2010;7:126-32. [PMID: 20397813 DOI: 10.3109/15412551003631733] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
94 Make B, Belfer MH. Primary Care Perspective on Chronic Obstructive Pulmonary Disease Management. Postgraduate Medicine 2015;123:145-52. [DOI: 10.3810/pgm.2011.03.2272] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
95 Sclar DA, Evans MA, Robison LM, Skaer TL. α1-Proteinase inhibitor (human) in the treatment of hereditary emphysema secondary to α1-antitrypsin deficiency: number and costs of years of life gained. Clin Drug Investig 2012;32:353-60. [PMID: 22480280 DOI: 10.2165/11631920-000000000-00000] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
96 Parr DG, Guest PG, Reynolds JH, Dowson LJ, Stockley RA. Prevalence and impact of bronchiectasis in alpha1-antitrypsin deficiency. Am J Respir Crit Care Med 2007;176:1215-21. [PMID: 17872489 DOI: 10.1164/rccm.200703-489OC] [Cited by in Crossref: 137] [Cited by in F6Publishing: 43] [Article Influence: 9.8] [Reference Citation Analysis]
97 Fregonese L, Stolk J. Hereditary alpha-1-antitrypsin deficiency and its clinical consequences. Orphanet J Rare Dis 2008;3:16. [PMID: 18565211 DOI: 10.1186/1750-1172-3-16] [Cited by in Crossref: 128] [Cited by in F6Publishing: 103] [Article Influence: 9.8] [Reference Citation Analysis]
98 Escribano A, Pastor S, Reula A, Castillo S, Vicente S, Sanz F, Casas F, Torres M, Fernández-fabrellas E, Codoñer-franch P, Dasí F. Accelerated telomere attrition in children and teenagers with α 1 -antitrypsin deficiency. Eur Respir J 2016;48:350-8. [DOI: 10.1183/13993003.00176-2016] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
99 Blanco I, Fernández-Bustillo E, de Serres FJ, Alkassam D, Rodríguez Menéndez C. [PI*S and PI*Z alpha 1-antitrypsin deficiency: estimated prevalence and number of deficient subjects in Spain]. Med Clin (Barc) 2004;123:761-5. [PMID: 15607066 DOI: 10.1016/s0025-7753(04)74661-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
100 Campos MA, Alazemi S, Zhang G, Wanner A, Salathe M, Baier H, Sandhaus RA. Exacerbations in subjects with alpha-1 antitrypsin deficiency receiving augmentation therapy. Respiratory Medicine 2009;103:1532-9. [DOI: 10.1016/j.rmed.2009.04.008] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 1.8] [Reference Citation Analysis]
101 Reilkoff R, Stephenson L. Fulminant hepatic failure in the setting of progressive ANCA-associated vasculitis associated with a rare alpha-1 antitrypsin phenotype, 'PiEE'. BMJ Case Rep 2018;2018:bcr-2017-222036. [PMID: 29592975 DOI: 10.1136/bcr-2017-222036] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
102 Gupta N, Gaudreault N, Thériault S, Li PZ, Henry C, Kirby M, Maltais F, Tan W, Bourbeau J, Bossé Y; Canadian Respiratory Research Network and the CanCOLD study group. Granularity of SERPINA1 alleles by DNA sequencing in CanCOLD. Eur Respir J 2020;56:2000958. [PMID: 32482783 DOI: 10.1183/13993003.00958-2020] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
103 Abboud RT, Ford GT, Chapman KR. Emphysema in alpha1-antitrypsin deficiency: does replacement therapy affect outcome? Treat Respir Med 2005;4:1-8. [PMID: 15725045 DOI: 10.2165/00151829-200504010-00001] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
104 Kandregula CAB, Smilin Bell Aseervatham G, Bentley GT, Kandasamy R. Alpha-1 antitrypsin: Associated diseases and therapeutic uses. Clin Chim Acta 2016;459:109-16. [PMID: 27259467 DOI: 10.1016/j.cca.2016.05.028] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
105 Campos M, Lascano J. Therapeutics: Alpha-1 Antitrypsin Augmentation Therapy. Methods Mol Biol 2017;1639:249-62. [PMID: 28752465 DOI: 10.1007/978-1-4939-7163-3_25] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
106 Pérez-Rubio G, Jiménez-Valverde LO, Ramírez-Venegas A, Camarena Á, Sansores RH, Flores-Trujillo F, Reséndiz-Hernández JM, Falfán-Valencia R. Prevalence of alpha-1 antitrypsin high-risk variants in Mexican mestizo population and their association with lung function values. Arch Bronconeumol 2015;51:80-5. [PMID: 25454901 DOI: 10.1016/j.arbres.2014.09.010] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
107 Suh-lailam BB, Procter M, Krautscheid P, Haas J, Kumar S, Mao R, Grenache DG. Challenging Identification of a Novel PiISF and the Rare PiMmaltonZ α1-Antitrypsin Deficiency Variants in Two Patients. American Journal of Clinical Pathology 2014;141:742-6. [DOI: 10.1309/ajcpr7eiqs8pimlv] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 1.1] [Reference Citation Analysis]
108 Tanash HA, Nilsson PM, Nilsson JA, Piitulainen E. Survival in severe alpha-1-antitrypsin deficiency (PiZZ). Respir Res 2010;11:44. [PMID: 20420704 DOI: 10.1186/1465-9921-11-44] [Cited by in Crossref: 38] [Cited by in F6Publishing: 30] [Article Influence: 3.5] [Reference Citation Analysis]
109 Mireles-Cabodevila E, Sahi H, Farver C, Mohammed TL, Culver DA. A young patient with a minimal smoking history presents with bullous emphysema and recurrent pneumothorax. Chest 2007;132:338-43. [PMID: 17625095 DOI: 10.1378/chest.06-2987] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
110 Cronin T, Rasheed E, Naughton A, McElvaney NG, Carroll TP, Crowley VEF, Conlon N. Serendipitous detection of α1-antitrypsin deficiency: a single institution's experience over a 32 month period. Clin Chem Lab Med 2021;59:e293-5. [PMID: 33544483 DOI: 10.1515/cclm-2020-1750] [Reference Citation Analysis]
111 Aiello M, Frizzelli A, Pisi R, Fantin A, Ghirardini M, Marchi L, Ferrarotti I, Bertorelli G, Percesepe A, Chetta A. Alpha-1 antitrypsin deficiency is significantly associated with atopy in asthmatic patients. J Asthma 2020;:1-8. [PMID: 32962473 DOI: 10.1080/02770903.2020.1827421] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
112 Chapman KR, Chorostowska-Wynimko J, Koczulla AR, Ferrarotti I, McElvaney NG. Alpha 1 antitrypsin to treat lung disease in alpha 1 antitrypsin deficiency: recent developments and clinical implications. Int J Chron Obstruct Pulmon Dis 2018;13:419-32. [PMID: 29430176 DOI: 10.2147/COPD.S149429] [Cited by in Crossref: 20] [Cited by in F6Publishing: 5] [Article Influence: 6.7] [Reference Citation Analysis]
113 Balduyck M, Odou MF, Zerimech F, Porchet N, Lafitte JJ, Maitre B. Diagnosis of alpha-1 antitrypsin deficiency: modalities, indications and diagnosis strategy. Rev Mal Respir 2014;31:729-45. [PMID: 25391508 DOI: 10.1016/j.rmr.2014.06.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
114 Stiles KM, Sondhi D, Kaminsky SM, De BP, Rosenberg JB, Crystal RG. Intrapleural Gene Therapy for Alpha-1 Antitrypsin Deficiency-Related Lung Disease. Chronic Obstr Pulm Dis 2018;5:244-57. [PMID: 30723782 DOI: 10.15326/jcopdf.5.4.2017.0160] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
115 Teckman J, Rosenthal P, Hawthorne K, Spino C, Bass LM, Murray KF, Kerkar N, Magee JC, Karpen S, Heubi JE, Molleston JP, Squires RH, Kamath BM, Guthery SL, Loomes KM, Sherker AH, Sokol RJ; ChiLDReN (Childhood Liver Disease Research Network). Longitudinal Outcomes in Young Patients with Alpha-1-Antitrypsin Deficiency with Native Liver Reveal that Neonatal Cholestasis is a Poor Predictor of Future Portal Hypertension. J Pediatr 2020;227:81-86.e4. [PMID: 32663593 DOI: 10.1016/j.jpeds.2020.07.031] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
116 Blanco I. Clinical Diagnosis. Blanco's Overview of Alpha-1 Antitrypsin Deficiency. Elsevier; 2017. pp. 115-28. [DOI: 10.1016/b978-0-12-809530-0.00009-x] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
117 Setoh K, Terao C, Muro S, Kawaguchi T, Tabara Y, Takahashi M, Nakayama T, Kosugi S, Sekine A, Yamada R, Mishima M, Matsuda F. Three missense variants of metabolic syndrome-related genes are associated with alpha-1 antitrypsin levels. Nat Commun 2015;6:7754. [PMID: 26174136 DOI: 10.1038/ncomms8754] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.7] [Reference Citation Analysis]
118 Mostafavi B, Piitulainen E, Tanash HA. Survival in the Swedish cohort with alpha-1-antitrypsin deficiency, up to the age of 43-45 years. Int J Chron Obstruct Pulmon Dis 2019;14:525-30. [PMID: 30880942 DOI: 10.2147/COPD.S183205] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
119 Miravitlles M, Soler-Cataluña JJ, Calle M, Molina J, Almagro P, Quintano JA, Trigueros JA, Cosío BG, Casanova C, Antonio Riesco J, Simonet P, Rigau D, Soriano JB, Ancochea J. Spanish Guidelines for Management of Chronic Obstructive Pulmonary Disease (GesEPOC) 2017. Pharmacological Treatment of Stable Phase. Arch Bronconeumol 2017;53:324-35. [PMID: 28477954 DOI: 10.1016/j.arbres.2017.03.018] [Cited by in Crossref: 237] [Cited by in F6Publishing: 213] [Article Influence: 59.3] [Reference Citation Analysis]
120 Köhnlein T, Rifai K. [Alpha1-antitrypsin deficiency]. Internist (Berl) 2010;51 Suppl 1:269-76. [PMID: 20135085 DOI: 10.1007/s00108-009-2505-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
121 Deshayes S, Martin Silva N, Grandhomme F, Khoy K, Mariotte D, Boutemy J, Maigné G, Brière-Bellier C, Delmas C, Bienvenu B, Lobbedez T, de Boysson H, Aouba A. Clinical Effect of Alpha-1 Antitrypsin Deficiency in Antineutrophil Cytoplasmic Antibody-associated Vasculitis: Results from a French Retrospective Monocentric Cohort. J Rheumatol 2019;46:1502-8. [PMID: 30824651 DOI: 10.3899/jrheum.180591] [Cited by in Crossref: 4] [Article Influence: 2.0] [Reference Citation Analysis]
122 Stoller JK, Tomashefski J, Crystal RG, Arroliga A, Strange C, Killian DN, Schluchter MD, Wiedemann HP. Mortality in Individuals With Severe Deficiency of α1-Antitrypsin. Chest 2005;127:1196-204. [DOI: 10.1016/s0012-3692(15)34467-6] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
123 Joly P, Lacan P, Chapuis-cellier C, Garcia C, Bererd M, Francina A. Molecular characterization of 7 new alpha-1 anti-trypsin (A1AT) variants including two with an associated deficient phenotype. Clinica Chimica Acta 2014;427:21-2. [DOI: 10.1016/j.cca.2013.09.017] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
124 Greulich T, Averyanov A, Borsa L, Rozborilová E, Vaicius D, Major T, Chopyak V, Tudorache V, Konstantinova T, Camprubí S. European screening for alpha 1 -antitrypsin deficiency in subjects with lung disease: European screening for AAT deficiency. The Clinical Respiratory Journal 2017;11:90-7. [DOI: 10.1111/crj.12310] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
125 DeLuca DS, Poluzioroviene E, Taminskiene V, Wrenger S, Utkus A, Valiulis A, Alasevičius T, Henderson J, Bush A, Welte T, Janciauskiene S, Valiulis A. SERPINA1 gene polymorphisms in a population-based ALSPAC cohort. Pediatr Pulmonol 2019;54:1474-8. [PMID: 31298815 DOI: 10.1002/ppul.24422] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
126 Blanco I, Bueno P, Diego I, Pérez-Holanda S, Casas-Maldonado F, Esquinas C, Miravitlles M. Alpha-1 antitrypsin Pi*Z gene frequency and Pi*ZZ genotype numbers worldwide: an update. Int J Chron Obstruct Pulmon Dis 2017;12:561-9. [PMID: 28243076 DOI: 10.2147/COPD.S125389] [Cited by in Crossref: 59] [Cited by in F6Publishing: 26] [Article Influence: 14.8] [Reference Citation Analysis]
127 Ljujic M, Divac Rankov A, Kojic S, Miranda E, Radojkovic D. Functional analysis of novel alpha-1 antitrypsin variants G320R and V321F. Mol Biol Rep 2014;41:6133-41. [PMID: 24969485 DOI: 10.1007/s11033-014-3492-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
128 Greenberg M, Smith RA. Support Seeking or Familial Obligation: An Investigation of Motives for Disclosing Genetic Test Results. Health Commun 2016;31:668-78. [PMID: 26507777 DOI: 10.1080/10410236.2014.989384] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
129 Crossley D, Stockley R, Sapey E. Alpha-1 Antitrypsin Deficiency and Accelerated Aging: A New Model for an Old Disease? Drugs Aging 2019;36:823-40. [PMID: 31179525 DOI: 10.1007/s40266-019-00684-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
130 Greulich T, Vogelmeier CF. Alpha-1-antitrypsin deficiency: increasing awareness and improving diagnosis. Ther Adv Respir Dis 2016;10:72-84. [PMID: 26341117 DOI: 10.1177/1753465815602162] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 5.2] [Reference Citation Analysis]
131 O'Brien ME, Fee L, Browne N, Carroll TP, Meleady P, Henry M, McQuillan K, Murphy MP, Logan M, McCarthy C, McElvaney OJ, Reeves EP, McElvaney NG. Activation of complement component 3 is associated with airways disease and pulmonary emphysema in alpha-1 antitrypsin deficiency. Thorax 2020;75:321-30. [PMID: 31959730 DOI: 10.1136/thoraxjnl-2019-214076] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 10.0] [Reference Citation Analysis]
132 Janciauskiene S, Ferrarotti I, Laenger F, Jonigk D, Luisetti M. Clinical utility gene card for: α-1-antitrypsin deficiency. Eur J Hum Genet 2011;19. [PMID: 21248733 DOI: 10.1038/ejhg.2010.246] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
133 Annunziata A, Ferrarotti I, Coppola A, Lanza M, Imitazione P, Spinelli S, Micco PD, Fiorentino G. Alpha-1 Antitrypsin Screening in a Selected Cohort of Patients Affected by Chronic Pulmonary Diseases in Naples, Italy. J Clin Med 2021;10:1546. [PMID: 33916947 DOI: 10.3390/jcm10081546] [Reference Citation Analysis]
134 Gumus A, Haziroglu M, Gunes Y. Association of serum magnesium levels with frequency of acute exacerbations in chronic obstructive pulmonary disease: a prospective study. Pulm Med 2014;2014:329476. [PMID: 25485151 DOI: 10.1155/2014/329476] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
135 Stocks JM, Brantly M, Pollock D, Barker A, Kueppers F, Strange C, Donohue JF, Sandhaus R. Multi-center study: the biochemical efficacy, safety and tolerability of a new alpha1-proteinase inhibitor, Zemaira. COPD 2006;3:17-23. [PMID: 17175661 DOI: 10.1080/15412550500493220] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 2.4] [Reference Citation Analysis]
136 Miravitlles M, Soler-Cataluña JJ, Calle M, Molina J, Almagro P, Quintano JA, Riesco JA, Trigueros JA, Piñera P, Simón A, López-Campos JL, Soriano JB, Ancochea J; Spanish Society of Pulmonology and Thoracic Surgery. Spanish COPD Guidelines (GesEPOC): pharmacological treatment of stable COPD. Spanish Society of Pulmonology and Thoracic Surgery. Arch Bronconeumol 2012;48:247-57. [PMID: 22561012 DOI: 10.1016/j.arbres.2012.04.001] [Cited by in Crossref: 165] [Cited by in F6Publishing: 161] [Article Influence: 18.3] [Reference Citation Analysis]
137 Seyama K, Hirai T, Mishima M, Tatsumi K, Nishimura M. A nationwide epidemiological survey of alpha1-antitrypsin deficiency in Japan. Respiratory Investigation 2016;54:201-6. [DOI: 10.1016/j.resinv.2015.12.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
138 Francalanci P, Santorelli FM, Saccani S, Bonetti MF, Medicina D, Coni P, Faa G, Callea F. Z and Mmalton-1-antitrypsin deficiency-associated hepatocellular carcinoma: a genetic study. Liver Int 2009;29:1593-6. [PMID: 19744266 DOI: 10.1111/j.1478-3231.2009.02091.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
139 Ottaviani S, Gorrini M, Scabini R, Kadija Z, Paracchini E, Mariani F, Ferrarotti I, Luisetti M. C reactive protein and alpha1-antitrypsin: relationship between levels and gene variants. Translational Research 2011;157:332-8. [DOI: 10.1016/j.trsl.2010.12.014] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 2.6] [Reference Citation Analysis]
140 Bagatin E, Jardim JRB, Stirbulov R. Doença pulmonar obstrutiva crônica ocupacional. J bras pneumol 2006;32:S35-40. [DOI: 10.1590/s1806-37132006000800007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
141 Strange C, Stoller JK, Sandhaus RA, Dickson R, Turino G. Results of a survey of patients with alpha-1 antitrypsin deficiency. Respiration 2006;73:185-90. [PMID: 16141711 DOI: 10.1159/000088061] [Cited by in Crossref: 38] [Cited by in F6Publishing: 31] [Article Influence: 2.4] [Reference Citation Analysis]
142 Guilemany J, Mullol J, Picado C. Relaciones entre rinosinusitis y bronquiectasias. Archivos de Bronconeumología 2006;42:135-40. [DOI: 10.1157/13085563] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
143 Poh TY, Mac Aogáin M, Chan AK, Yii AC, Yong VF, Tiew PY, Koh MS, Chotirmall SH. Understanding COPD-overlap syndromes. Expert Rev Respir Med 2017;11:285-98. [PMID: 28282995 DOI: 10.1080/17476348.2017.1305895] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 6.3] [Reference Citation Analysis]
144 Campos MA, Alazemi S, Zhang G, Sandhaus RA, Wanner A. Influenza Vaccination in Subjects With α 1 -Antitrypsin Deficiency. Chest 2008;133:49-55. [DOI: 10.1378/chest.07-1482] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
145 Miravitlles M. Alpha-1-antitrypsin and other proteinase inhibitors. Curr Opin Pharmacol 2012;12:309-14. [PMID: 22365503 DOI: 10.1016/j.coph.2012.02.004] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 2.8] [Reference Citation Analysis]
146 Teckman JH. Alpha-1-Antitrypsin Deficiency Liver Disease. Alpha-1-antitrypsin Deficiency. Elsevier; 2017. pp. 117-31. [DOI: 10.1016/b978-0-12-803942-7.00008-8] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
147 Mwirigi NW, Thomas CF. Hypersensitivity vasculitis with leukocytoclastic vasculitis associated with alpha-1-proteinase inhibitor. Case Rep Med 2009;2009:941258. [PMID: 20204065 DOI: 10.1155/2009/941258] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
148 Wanner A, Groft SC, Teagarden JR, Krischer J, Davis BR, Coffey CS, Hickam DH, Teckman J, Nelson DR, McCaleb ML, Loomba R, Strange C, Sandhaus RA, Brantly M, Edelman JM, Farrugia A. Clinical Trial Design for Alpha-1 Antitrypsin Deficiency: A Model for Rare Diseases. Chronic Obstr Pulm Dis 2015;2:177-90. [PMID: 28848840 DOI: 10.15326/jcopdf.2.2.2015.0132] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
149 Wewers MD, Crystal RG. Alpha-1 Antitrypsin Augmentation Therapy. COPD: Journal of Chronic Obstructive Pulmonary Disease 2013;10:64-7. [DOI: 10.3109/15412555.2013.764402] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 3.6] [Reference Citation Analysis]
150 Bernspång E, Wollmer P, Sveger T, Piitulainen E. Lung function in 30-year-old alpha-1-antitrypsin-deficient individuals. Respiratory Medicine 2009;103:861-5. [DOI: 10.1016/j.rmed.2008.12.021] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
151 Kelly E, Greene CM, Carroll TP, Mcelvaney NG, O’neill SJ. Alpha-1 antitrypsin deficiency. Respiratory Medicine CME 2011;4:1-8. [DOI: 10.1016/j.rmedc.2011.04.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
152 Chorostowska-Wynimko J. Disease Modification in Emphysema Related to Alpha-1 Antitrypsin Deficiency. COPD 2016;13:807-15. [PMID: 27172295 DOI: 10.1080/15412555.2016.1178224] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
153 Zerimech F, Hennache G, Bellon F, Barouh G, Jacques Lafitte J, Porchet N, Balduyck M. Evaluation of a new Sebia isoelectrofocusing kit for alpha 1-antitrypsin phenotyping with the Hydrasys System. Clin Chem Lab Med 2008;46:260-3. [PMID: 18076352 DOI: 10.1515/CCLM.2008.036] [Cited by in Crossref: 32] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
154 Ferrarotti I, Ottaviani S. Laboratory diagnosis of AATD. In: Strnad P, Brantly ML, Bals R, editors. α 1 -Antitrypsin Deficiency. Sheffield: European Respiratory Society; 2019. pp. 39-51. [DOI: 10.1183/2312508x.10032418] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
155 Herrera EM, Joseph C, Brouwer ES, Gandhi V, Czorniak M. Alpha-1 Antitrypsin Deficiency-Associated Clinical Manifestations and Healthcare Resource Use in the United States. COPD 2021;18:315-24. [PMID: 34036848 DOI: 10.1080/15412555.2021.1917532] [Reference Citation Analysis]
156 Hogan G, Geoghegan P, Carroll TP, Clarke J, McElvaney OF, McElvaney OJ, McElvaney NG, Curley GF. α1-Antitrypsin: Key Player or Bystander in Acute Respiratory Distress Syndrome? Anesthesiology 2021;134:792-808. [PMID: 33721888 DOI: 10.1097/ALN.0000000000003727] [Reference Citation Analysis]
157 Chiuchiolo MJ, Kaminsky SM, Sondhi D, Mancenido D, Hollmann C, Crystal RG. Phase I/II Study of Intrapleural Administration of a Serotype rh.10 Replication-Deficient Adeno-Associated Virus Gene Transfer Vector Expressing the Human α1-Antitrypsin cDNA to Individuals with α1-Antitrypsin Deficiency. Human Gene Therapy Clinical Development 2014;25:112-33. [DOI: 10.1089/humc.2014.2513] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
158 Balderacchi AM, Barzon V, Ottaviani S, Corino A, Zorzetto M, Wencker M, Corsico AG, Ferrarotti I. Comparison of different algorithms in laboratory diagnosis of alpha1-antitrypsin deficiency. Clin Chem Lab Med 2021;59:1384-91. [PMID: 33675199 DOI: 10.1515/cclm-2020-1881] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
159 Wise RA, Tashkin DP. Preventing chronic obstructive pulmonary disease: what is known and what needs to be done to make a difference to the patient? Am J Med 2007;120:S14-22. [PMID: 17678939 DOI: 10.1016/j.amjmed.2007.04.008] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
160 Petrache I, Fijalkowska I, Zhen L, Medler TR, Brown E, Cruz P, Choe KH, Taraseviciene-Stewart L, Scerbavicius R, Shapiro L, Zhang B, Song S, Hicklin D, Voelkel NF, Flotte T, Tuder RM. A novel antiapoptotic role for alpha1-antitrypsin in the prevention of pulmonary emphysema. Am J Respir Crit Care Med 2006;173:1222-8. [PMID: 16514110 DOI: 10.1164/rccm.200512-1842OC] [Cited by in Crossref: 141] [Cited by in F6Publishing: 75] [Article Influence: 9.4] [Reference Citation Analysis]
161 Clark VC, Dhanasekaran R, Brantly M, Rouhani F, Schreck P, Nelson DR. Liver test results do not identify liver disease in adults with α(1)-antitrypsin deficiency. Clin Gastroenterol Hepatol 2012;10:1278-83. [PMID: 22835581 DOI: 10.1016/j.cgh.2012.07.007] [Cited by in Crossref: 38] [Cited by in F6Publishing: 25] [Article Influence: 4.2] [Reference Citation Analysis]
162 Sandhaus RA, Turino G, Stocks J, Strange C, Trapnell BC, Silverman EK, Everett SE, Stoller JK. α1-Antitrypsin Augmentation Therapy for PI*MZ Heterozygotes. Chest 2008;134:831-4. [DOI: 10.1378/chest.08-0868] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 2.3] [Reference Citation Analysis]
163 Köhnlein T, Janciauskiene S, Welte T. Diagnostic delay and clinical modifiers in alpha-1 antitrypsin deficiency. Ther Adv Respir Dis 2010;4:279-87. [PMID: 20660539 DOI: 10.1177/1753465810376407] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 2.8] [Reference Citation Analysis]
164 Parr DG, Stoel BC, Stolk J, Stockley RA. Pattern of emphysema distribution in alpha1-antitrypsin deficiency influences lung function impairment. Am J Respir Crit Care Med. 2004;170:1172-1178. [PMID: 15306534 DOI: 10.1164/rccm.200406-761oc] [Cited by in Crossref: 141] [Cited by in F6Publishing: 52] [Article Influence: 8.3] [Reference Citation Analysis]
165 Greene CM, McElvaney NG. Z α-1 antitrypsin deficiency and the endoplasmic reticulum stress response. World J Gastrointest Pharmacol Ther 2010; 1(5): 94-101 [PMID: 21577302 DOI: 10.4292/wjgpt.v1.i5.94] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
166 Luisetti M, Balfour-lynn IM, Johnson SR, Miravitlles M, Strange C, Trapnell BC, van Bronswijk H, Vogelmeier C. Perspectives for improving the evaluation and access of therapies for rare lung diseases in Europe. Respiratory Medicine 2012;106:759-68. [DOI: 10.1016/j.rmed.2012.02.016] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
167 Turner AM, Stolk J, Bals R, Lickliter JD, Hamilton J, Christianson DR, Given BD, Burdon JG, Loomba R, Stoller JK, Teckman JH. Hepatic-targeted RNA interference provides robust and persistent knockdown of alpha-1 antitrypsin levels in ZZ patients. J Hepatol 2018;69:378-84. [PMID: 29572094 DOI: 10.1016/j.jhep.2018.03.012] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 10.7] [Reference Citation Analysis]
168 Gramegna A, Aliberti S, Confalonieri M, Corsico A, Richeldi L, Vancheri C, Blasi F. Alpha-1 antitrypsin deficiency as a common treatable mechanism in chronic respiratory disorders and for conditions different from pulmonary emphysema? A commentary on the new European Respiratory Society statement. Multidiscip Respir Med 2018;13:39. [PMID: 30338069 DOI: 10.1186/s40248-018-0153-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
169 Seixas S, Marques PI. Known Mutations at the Cause of Alpha-1 Antitrypsin Deficiency an Updated Overview of SERPINA1 Variation Spectrum. Appl Clin Genet 2021;14:173-94. [PMID: 33790624 DOI: 10.2147/TACG.S257511] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
170 Tanash HA, Piitulainen E. Liver disease in adults with severe alpha-1-antitrypsin deficiency. J Gastroenterol 2019;54:541-8. [PMID: 30680526 DOI: 10.1007/s00535-019-01548-y] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 10.0] [Reference Citation Analysis]
171 Gómez-Mariano G, Matamala N, Martínez S, Justo I, Marcacuzco A, Jimenez C, Monzón S, Cuesta I, Garfia C, Martínez MT, Huch M, Pérez de Castro I, Posada M, Janciauskiene S, Martínez-Delgado B. Liver organoids reproduce alpha-1 antitrypsin deficiency-related liver disease. Hepatol Int 2020;14:127-37. [PMID: 31832977 DOI: 10.1007/s12072-019-10007-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
172 Campos MA, Kueppers F, Stocks JM, Strange C, Chen J, Griffin R, Wang-smith L, Brantly ML. Safety and Pharmacokinetics of 120 mg/kg versus 60 mg/kg Weekly Intravenous Infusions of Alpha-1 Proteinase Inhibitor in Alpha-1 Antitrypsin Deficiency: A Multicenter, Randomized, Double-Blind, Crossover Study (SPARK). COPD: Journal of Chronic Obstructive Pulmonary Disease 2013;10:687-95. [DOI: 10.3109/15412555.2013.800852] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 4.4] [Reference Citation Analysis]
173 McGee D, Strange C, McClure R, Schwarz L, Erven M. The Alpha-1 Association Genetic Counseling Program: an innovative approach to service. J Genet Couns 2011;20:330-6. [PMID: 21424325 DOI: 10.1007/s10897-011-9355-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
174 Riley L, Brantly M, Ataya A. A Woman With Dyspnea and Bronchiectasis. JAMA 2019;322:571-2. [PMID: 31276152 DOI: 10.1001/jama.2019.8606] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
175 Kadota T, Fujita Y, Yoshioka Y, Araya J, Kuwano K, Ochiya T. Extracellular Vesicles in Chronic Obstructive Pulmonary Disease. Int J Mol Sci 2016;17:E1801. [PMID: 27801806 DOI: 10.3390/ijms17111801] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 7.0] [Reference Citation Analysis]
176 Stoller JK. Detecting Alpha-1 Antitrypsin Deficiency. Annals ATS 2016;13:S317-25. [DOI: 10.1513/annalsats.201506-349kv] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.4] [Reference Citation Analysis]
177 Scarlata S, Santangelo S, Ferrarotti I, Corsico AG, Ottaviani S, Finamore P, Fontana D, Miravitlles M, Incalzi RA. Electrophoretic α 1 -globulin for screening of α 1 -antitrypsin deficient variants. Clinical Chemistry and Laboratory Medicine (CCLM) 2020;58:1837-45. [DOI: 10.1515/cclm-2020-0071] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
178 Stockley RA, Edgar RG, Pillai A, Turner AM. Individualized lung function trends in alpha-1-antitrypsin deficiency: a need for patience in order to provide patient centered management? Int J Chron Obstruct Pulmon Dis 2016;11:1745-56. [PMID: 27536086 DOI: 10.2147/COPD.S111508] [Cited by in Crossref: 22] [Cited by in F6Publishing: 13] [Article Influence: 4.4] [Reference Citation Analysis]
179 Al Ashry HS, Strange C. COPD in individuals with the PiMZ alpha-1 antitrypsin genotype. Eur Respir Rev 2017;26:170068. [PMID: 29070580 DOI: 10.1183/16000617.0068-2017] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
180 Yusen RD, Criner GJ, Sternberg AL, Au DH, Fuhlbrigge AL, Albert RK, Casaburi R, Stoller JK, Harrington KF, Cooper JAD Jr, Diaz P, Gay S, Kanner R, MacIntyre N, Martinez FJ, Piantadosi S, Sciurba F, Shade D, Stibolt T, Tonascia J, Wise R, Bailey WC; LOTT Research Group *., LOTT Research Group. The Long-Term Oxygen Treatment Trial for Chronic Obstructive Pulmonary Disease: Rationale, Design, and Lessons Learned. Ann Am Thorac Soc 2018;15:89-101. [PMID: 29087741 DOI: 10.1513/AnnalsATS.201705-374SD] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
181 Pérez V, Ibernón M, López D, Pastor MC, Navarro M, Navarro-Muñoz M, Bonet J, Romero R. Urinary peptide profiling to differentiate between minimal change disease and focal segmental glomerulosclerosis. PLoS One 2014;9:e87731. [PMID: 24498182 DOI: 10.1371/journal.pone.0087731] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
182 Ferrarotti I, Poplawska-Wisniewska B, Trevisan MT, Koepke J, Dresel M, Koczulla R, Ottaviani S, Baldo R, Gorrini M, Sala G, Cavallon L, Welte T, Chorostowska-Wynimko J, Luisetti M, Janciauskiene S. How Can We Improve the Detection of Alpha1-Antitrypsin Deficiency? PLoS One 2015;10:e0135316. [PMID: 26270547 DOI: 10.1371/journal.pone.0135316] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
183 Strnad P, Buch S, Hamesch K, Fischer J, Rosendahl J, Schmelz R, Brueckner S, Brosch M, Heimes CV, Woditsch V, Scholten D, Nischalke HD, Janciauskiene S, Mandorfer M, Trauner M, Way MJ, Mcquillin A, Reichert MC, Krawczyk M, Casper M, Lammert F, Braun F, von Schönfels W, Hinz S, Burmeister G, Hellerbrand C, Teufel A, Feldman A, Schattenberg JM, Bantel H, Pathil A, Demir M, Kluwe J, Boettler T, Ridinger M, Wodarz N, Soyka M, Rietschel M, Kiefer F, Weber T, Marhenke S, Vogel A, Hinrichsen H, Canbay A, Schlattjan M, Sosnowsky K, Sarrazin C, von Felden J, Geier A, Deltenre P, Sipos B, Schafmayer C, Nothnagel M, Aigner E, Datz C, Stickel F, Morgan MY, Hampe J, Berg T, Trautwein C. Heterozygous carriage of the alpha1-antitrypsin Pi*Z variant increases the risk to develop liver cirrhosis. Gut 2019;68:1099-107. [DOI: 10.1136/gutjnl-2018-316228] [Cited by in Crossref: 53] [Cited by in F6Publishing: 48] [Article Influence: 17.7] [Reference Citation Analysis]
184 Kueppers F, Andrake MD, Xu Q, Dunbrack RL Jr, Kim J, Sanders CL. Protein modeling to assess the pathogenicity of rare variants of SERPINA1 in patients suspected of having Alpha 1 Antitrypsin Deficiency. BMC Med Genet 2019;20:125. [PMID: 31307431 DOI: 10.1186/s12881-019-0852-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
185 Greene CM, Marciniak SJ, Teckman J, Ferrarotti I, Brantly ML, Lomas DA, Stoller JK, McElvaney NG. α1-Antitrypsin deficiency. Nat Rev Dis Primers 2016;2:16051. [PMID: 27465791 DOI: 10.1038/nrdp.2016.51] [Cited by in Crossref: 103] [Cited by in F6Publishing: 98] [Article Influence: 20.6] [Reference Citation Analysis]
186 Rahaghi F, Ortega I, Rahaghi N, Oliveira E, Ramirez J, Smolley L, Stoller JK. Physician Alert Suggesting Alpha-1 Antitrypsin Deficiency Testing in Pulmonary Function Test (PFT) Results. COPD: Journal of Chronic Obstructive Pulmonary Disease 2009;6:26-30. [DOI: 10.1080/15412550802587927] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
187 Sitkauskiene B, Serapinas D, Blanco I, Fernández-bustillo E, Janciauskiene S, Sakalauskas R. Screening for alpha1-antitrypsin deficiency in Lithuanian patients with COPD. Respiratory Medicine 2008;102:1654-8. [DOI: 10.1016/j.rmed.2008.07.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
188 Rachmiel M, Strauss P, Dror N, Benzaquen H, Horesh O, Tov N, Weintrob N, Landau Z, Ben-ami M, Haim A, Phillip M, Bistritzer T, Lewis EC, Lebenthal Y. Alpha-1 antitrypsin therapy is safe and well tolerated in children and adolescents with recent onset type 1 diabetes mellitus: Alpha-1 antitrypsin is safe in diabetic youth. Pediatr Diabetes 2016;17:351-9. [DOI: 10.1111/pedi.12283] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 2.8] [Reference Citation Analysis]
189 Veith M, Tüffers J, Peychev E, Klemmer A, Kotke V, Janciauskiene S, Wilhelm S, Bals R, Koczulla AR, Vogelmeier CF, Greulich T. The Distribution of Alpha-1 Antitrypsin Genotypes Between Patients with COPD/Emphysema, Asthma and Bronchiectasis. Int J Chron Obstruct Pulmon Dis 2020;15:2827-36. [PMID: 33192056 DOI: 10.2147/COPD.S271810] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
190 Blanco LE, de Serres FJ, Fernańdez-bustillo E, Kassam DA, Arbesú D, Rodríguez C, Torre JC. α1-Antitrypsin and fibromyalgia: new data in favour of the inflammatory hypothesis of fibromyalgia. Medical Hypotheses 2005;64:759-69. [DOI: 10.1016/j.mehy.2004.10.005] [Cited by in Crossref: 26] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
191 Stockley RA. Antitrypsin Deficiency Assessment and Programme for Treatment (ADAPT): The United Kingdom Registry. COPD 2015;12 Suppl 1:63-8. [PMID: 25938295 DOI: 10.3109/15412555.2015.1021911] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
192 Rodríguez E, Ferrer J, Martí S, Zock JP, Plana E, Morell F. Impact of occupational exposure on severity of COPD. Chest 2008;134:1237-43. [PMID: 18689596 DOI: 10.1378/chest.08-0622] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 1.9] [Reference Citation Analysis]
193 McGee D, Schwarz L, McClure R, Peterka L, Rouhani F, Brantly M, Strange C. Is PiSS Alpha-1 Antitrypsin Deficiency Associated with Disease? Pulm Med 2010;2010:570679. [PMID: 21687342 DOI: 10.1155/2010/570679] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
194 Ferreira TC, Sampaio EP, Argañaraz GA, Gondim MV, Shapiro L, Argañaraz ER. Increased prevalence of the alpha-1-antitrypsin (A1AT) deficiency-related S gene in patients infected with human immunodeficiency virus type 1. J Med Virol 2014;86:23-9. [PMID: 24122823 DOI: 10.1002/jmv.23759] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
195 Häggblom J, Kettunen K, Karjalainen J, Heliövaara M, Jousilahti P, Saarelainen S. Prevalence of PI*Z and PI*S alleles of alpha-1-antitrypsin deficiency in Finland. Eur Clin Respir J 2015;2:28829. [PMID: 26672964 DOI: 10.3402/ecrj.v2.28829] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
196 Holme J, Stockley RA. Radiologic and Clinical Features of COPD Patients With Discordant Pulmonary Physiology. Chest 2007;132:909-15. [DOI: 10.1378/chest.07-0341] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 2.8] [Reference Citation Analysis]
197 Milger K, Holdt LM, Teupser D, Huber RM, Behr J, Kneidinger N. Identification of a novel SERPINA-1 mutation causing alpha-1 antitrypsin deficiency in a patient with severe bronchiectasis and pulmonary embolism. Int J Chron Obstruct Pulmon Dis 2015;10:891-7. [PMID: 26005342 DOI: 10.2147/COPD.S80173] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
198 Segal LN, Martinez FJ. Chronic obstructive pulmonary disease subpopulations and phenotyping. J Allergy Clin Immunol 2018;141:1961-71. [PMID: 29884286 DOI: 10.1016/j.jaci.2018.02.035] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 7.5] [Reference Citation Analysis]
199 Hackbarth JS, Tostrud LJ, Rumilla KM, Krowka MJ, Snyder MR. Discordant alpha-1 antitrypsin phenotype and genotype results in a liver transplant patient. Clinica Chimica Acta 2010;411:1146-8. [DOI: 10.1016/j.cca.2010.03.038] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
200 Brode SK, Ling SC, Chapman KR. Alpha-1 antitrypsin deficiency: a commonly overlooked cause of lung disease. CMAJ 2012;184:1365-71. [PMID: 22761482 DOI: 10.1503/cmaj.111749] [Cited by in Crossref: 48] [Cited by in F6Publishing: 38] [Article Influence: 5.3] [Reference Citation Analysis]
201 Cuvelier A. Le déficit en alpha-1 antitrypsine. Revue des Maladies Respiratoires 2007;24:7-17. [DOI: 10.1016/s0761-8425(07)92773-4] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
202 Basil N, Ekström M, Piitulainen E, Lindberg A, Rönmark E, Jehpsson L, Tanash H. Severe alpha-1-antitrypsin deficiency increases the risk of venous thromboembolism. J Thromb Haemost 2021;19:1519-25. [PMID: 33763945 DOI: 10.1111/jth.15302] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
203 Vidal R, Blanco I, Casas F, Jardí R, Miravitlles M. Guidelines for the Diagnosis and Management of α1-Antitrypsin Deficiency. Archivos de Bronconeumología ((English Edition)) 2006;42:645-59. [DOI: 10.1016/s1579-2129(07)60007-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 21] [Article Influence: 0.4] [Reference Citation Analysis]
204 Ferrarotti I, Gorrini M, Scabini R, Ottaviani S, Mazzola P, Campo I, Zorzetto M, Luisetti M. Secondary outputs of alpha1-antitrypsin deficiency targeted detection programme. Respiratory Medicine 2008;102:354-8. [DOI: 10.1016/j.rmed.2007.10.015] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
205 Schmid ST, Koepke J, Dresel M, Hattesohl A, Frenzel E, Perez J, Lomas DA, Miranda E, Greulich T, Noeske S, Wencker M, Teschler H, Vogelmeier C, Janciauskiene S, Koczulla AR. The effects of weekly augmentation therapy in patients with PiZZ α1-antitrypsin deficiency. Int J Chron Obstruct Pulmon Dis 2012;7:687-96. [PMID: 23055718 DOI: 10.2147/COPD.S34560] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.1] [Reference Citation Analysis]
206 Leap J, Arshad O, Cheema T, Balaan M. Pathophysiology of COPD. Crit Care Nurs Q 2021;44:2-8. [PMID: 33234854 DOI: 10.1097/CNQ.0000000000000334] [Reference Citation Analysis]
207 Stoller JK, Piliang M. Panniculitis in Alpha-1 Antitrypsin Deficiency: A Review. Clinical Pulmonary Medicine 2008;15:113-7. [DOI: 10.1097/cpm.0b013e3181672239] [Cited by in Crossref: 11] [Article Influence: 0.8] [Reference Citation Analysis]
208 Bradi AC, Audisho N, Casey DK, Chapman KR. Alpha-1 antitrypsin deficiency in Canada: regional disparities in diagnosis and management. COPD 2015;12 Suppl 1:15-21. [PMID: 25938286 DOI: 10.3109/15412555.2015.1021908] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
209 Ringenbach MR, Banta E, Snyder MR, Craig TJ, Ishmael FT. A challenging diagnosis of alpha-1-antitrypsin deficiency: identification of a patient with a novel F/Null phenotype. Allergy Asthma Clin Immunol 2011;7:18. [PMID: 22078084 DOI: 10.1186/1710-1492-7-18] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
210 Campos M, Shmuels D, Walsh J. Detection of alpha-1 antitrypsin deficiency in the US. Am J Med 2012;125:623-4. [PMID: 22560171 DOI: 10.1016/j.amjmed.2011.12.014] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
211 Krishna G, Sankaranarayanan V, Chitkara RK. New therapies for chronic obstructive pulmonary disease. Expert Opin Investig Drugs 2004;13:255-67. [PMID: 15013944 DOI: 10.1517/13543784.13.3.255] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
212 Quast TM, Self AR, Browning RF. Diagnostic Evaluation of Bronchiectasis. Disease-a-Month 2008;54:527-39. [DOI: 10.1016/j.disamonth.2008.05.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
213 Mcelvaney NG. Diagnosing α 1 -antitrypsin deficiency: how to improve the current algorithm. Eur Respir Rev 2015;24:52-7. [DOI: 10.1183/09059180.10010814] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 4.8] [Reference Citation Analysis]
214 Ko DH, Chang HE, Song SH, Yoon H, Park KU, Song J. Identification of compound heterozygous mutation in a Korean patient with alpha 1-antitrypsin deficiency. Korean J Lab Med. 2011;31:294-297. [PMID: 22016686 DOI: 10.3343/kjlm.2011.31.4.294] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
215 Oliveira MJ, Seixas S, Ladeira I, Monteiro R, Shiang T, Guimarães M, Lima R. Alpha-1 antitrypsin deficiency caused by a novel mutation (p.Leu263Pro): Pi*ZQ0gaia - Q0gaia allele. Rev Port Pneumol (2006) 2015:S2173-5115(15)00133-5. [PMID: 26281944 DOI: 10.1016/j.rppnen.2015.07.002] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
216 Lara B, Martínez MT, Blanco I, Hernández-Moro C, Velasco EA, Ferrarotti I, Rodriguez-Frias F, Perez L, Vazquez I, Alonso J, Posada M, Martínez-Delgado B. Severe alpha-1 antitrypsin deficiency in composite heterozygotes inheriting a new splicing mutation QOMadrid. Respir Res 2014;15:125. [PMID: 25287719 DOI: 10.1186/s12931-014-0125-y] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 3.9] [Reference Citation Analysis]
217 Green C, Parr D, Edgar R, Stockley R, Turner A. Lung density associates with survival in alpha 1 antitrypsin deficient patients. Respiratory Medicine 2016;112:81-7. [DOI: 10.1016/j.rmed.2016.01.007] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 3.4] [Reference Citation Analysis]
218 Zamora NP, Pla RV, Del Rio PG, Margaleff RJ, Frias FR, Ronsano JB. Intravenous human plasma-derived augmentation therapy in alpha 1-antitrypsin deficiency: from pharmacokinetic analysis to individualizing therapy. Ann Pharmacother 2008;42:640-6. [PMID: 18413692 DOI: 10.1345/aph.1K505] [Cited by in Crossref: 14] [Cited by in F6Publishing: 3] [Article Influence: 1.1] [Reference Citation Analysis]
219 Bozarth AL, Covey A, Gohar A, Salzman G. Chronic Obstructive Pulmonary Disease: Clinical Review and Update on Consensus Guidelines. Hospital Practice 2015;42:79-91. [DOI: 10.3810/hp.2014.02.1095] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
220 Qamar AA, Burke SK, Lafleur JD, Ding BC, Bland KS, Wong MD, Gustafson PN, Blair AT, Franano FN. The ability of serum from alpha 1-antitrypsin-deficient patients to inhibit PRT-201, a recombinant human type I pancreatic elastase. Biotechnol Appl Biochem 2012;59:22-8. [PMID: 22332741 DOI: 10.1002/bab.65] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
221 Greene CM, Hassan T, Molloy K, McElvaney NG. The role of proteases, endoplasmic reticulum stress and SERPINA1 heterozygosity in lung disease and α-1 anti-trypsin deficiency. Expert Rev Respir Med 2011;5:395-411. [PMID: 21702661 DOI: 10.1586/ers.11.20] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
222 Traclet J, Delaval P, Terrioux P, Mornex JF. Augmentation therapy of alpha-1 antitrypsin deficiency associated emphysema. Rev Mal Respir 2015;32:435-46. [PMID: 25908241 DOI: 10.1016/j.rmr.2014.10.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
223 Molina J, Flor X, García R, Timiraos R, Tirado-Conde G, Miravitlles M. The IDDEA project: a strategy for the detection of alpha-1 antitrypsin deficiency in COPD patients in the primary care setting. Ther Adv Respir Dis 2011;5:237-43. [PMID: 21652608 DOI: 10.1177/1753465811404919] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
224 Dżeljilji A, Rokicki W, Karuś K. Selected metabolic aspects of elastin and collagen fiber proteolysis in diseases of the respiratory system - the significance of α1 antitrypsin deficiency. Kardiochir Torakochirurgia Pol 2016;13:242-7. [PMID: 27785139 DOI: 10.5114/kitp.2016.62614] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
225 Stevens B, Krstic N, Jones M, Murphy L, Hoskovec J. Finding Middle Ground in Constructing a Clinically Useful Expanded Carrier Screening Panel. Obstetrics & Gynecology 2017;130:279-84. [DOI: 10.1097/aog.0000000000002139] [Cited by in Crossref: 28] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]
226 Stoller JK, Aboussouan LS. Alpha1-antitrypsin deficiency. Lancet. 2005;365:2225-2236. [PMID: 15978931 DOI: 10.1016/s0140-6736(05)66781-5] [Cited by in Crossref: 386] [Cited by in F6Publishing: 121] [Article Influence: 24.1] [Reference Citation Analysis]
227 Esquinas C, Barrecheguren M, Sucena M, Rodriguez E, Fernandez S, Miravitlles M. Practice and knowledge about diagnosis and treatment of alpha-1 antitrypsin deficiency in Spain and Portugal. BMC Pulm Med 2016;16. [DOI: 10.1186/s12890-016-0222-4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 4] [Article Influence: 3.2] [Reference Citation Analysis]
228 Chan ED, Kaminska AM, Gill W, Chmura K, Feldman NE, Bai X, Floyd CM, Fulton KE, Huitt GA, Strand MJ, Iseman MD, Shapiro L. Alpha-1-antitrypsin (AAT) anomalies are associated with lung disease due to rapidly growing mycobacteria and AAT inhibits Mycobacterium abscessus infection of macrophages. Scandinavian Journal of Infectious Diseases 2009;39:690-6. [DOI: 10.1080/00365540701225744] [Cited by in Crossref: 75] [Cited by in F6Publishing: 64] [Article Influence: 6.3] [Reference Citation Analysis]
229 Eden E, Turino GM. α 1 -Antitrypsin Deficiency. Chest 2009;135:591-2. [DOI: 10.1378/chest.08-2622] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
230 Thun GA, Imboden M, Ferrarotti I, Kumar A, Obeidat M, Zorzetto M, Haun M, Curjuric I, Couto Alves A, Jackson VE, Albrecht E, Ried JS, Teumer A, Lopez LM, Huffman JE, Enroth S, Bossé Y, Hao K, Timens W, Gyllensten U, Polasek O, Wilson JF, Rudan I, Hayward C, Sandford AJ, Deary IJ, Koch B, Reischl E, Schulz H, Hui J, James AL, Rochat T, Russi EW, Jarvelin MR, Strachan DP, Hall IP, Tobin MD, Dahl M, Fallgaard Nielsen S, Nordestgaard BG, Kronenberg F, Luisetti M, Probst-Hensch NM. Causal and synthetic associations of variants in the SERPINA gene cluster with alpha1-antitrypsin serum levels. PLoS Genet 2013;9:e1003585. [PMID: 23990791 DOI: 10.1371/journal.pgen.1003585] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 4.3] [Reference Citation Analysis]
231 Sanfeliu A, Hokamp K, Gill M, Tropea D. Transcriptomic Analysis of Mecp2 Mutant Mice Reveals Differentially Expressed Genes and Altered Mechanisms in Both Blood and Brain. Front Psychiatry 2019;10:278. [PMID: 31110484 DOI: 10.3389/fpsyt.2019.00278] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
232 Sandhaus RA, Knebel AR. Might your respiratory patient have alpha-1 antitrypsin deficiency? Heart Lung 2015;44:463-4. [PMID: 26260071 DOI: 10.1016/j.hrtlng.2015.07.003] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
233 Gross NJ, Giembycz MA, Rennard SI. Treatment of Chronic Obstructive Pulmonary Disease with Roflumilast, a New Phosphodiesterase 4 Inhibitor. COPD: Journal of Chronic Obstructive Pulmonary Disease 2010;7:141-53. [DOI: 10.3109/15412551003758304] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 4.0] [Reference Citation Analysis]
234 Rahaghi F, Omert L, Clark V, Sandhaus RA. Managing the Alpha-1 patient in the ICU: Adapting broad critical care strategies in AATD. J Crit Care 2019;54:212-9. [PMID: 31614323 DOI: 10.1016/j.jcrc.2019.08.027] [Reference Citation Analysis]
235 Corda L, Medicina D, La Piana GE, Bertella E, Moretti G, Bianchi L, Pinelli V, Savoldi G, Baiardi P, Facchetti F, Gatta N, Annesi-Maesano I, Balbi B. Population genetic screening for alpha1-antitrypsin deficiency in a high-prevalence area. Respiration 2011;82:418-25. [PMID: 21474916 DOI: 10.1159/000325067] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
236 Anderson D, Macnee W. Targeted treatment in COPD: a multi-system approach for a multi-system disease. Int J Chron Obstruct Pulmon Dis 2009;4:321-35. [PMID: 19750192 DOI: 10.2147/copd.s2999] [Cited by in Crossref: 39] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
237 Calle Rubio M, Soriano JB, López-Campos JL, Soler-Cataluña JJ, Alcázar Navarrete B, Rodríguez González-Moro JM, Miravitlles M, Barrecheguren M, Fuentes Ferrer ME, Rodriguez Hermosa JL; EPOCONSUL Study. Testing for alpha-1 antitrypsin in COPD in outpatient respiratory clinics in Spain: A multilevel, cross-sectional analysis of the EPOCONSUL study. PLoS One 2018;13:e0198777. [PMID: 29953442 DOI: 10.1371/journal.pone.0198777] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
238 Blanco I, Béritze N, Argüelles M, Cárcaba V, Fernández F, Janciauskiene S, Oikonomopoulou K, de Serres FJ, Fernández-Bustillo E, Hollenberg MD. Abnormal overexpression of mastocytes in skin biopsies of fibromyalgia patients. Clin Rheumatol 2010;29:1403-12. [PMID: 20428906 DOI: 10.1007/s10067-010-1474-7] [Cited by in Crossref: 50] [Cited by in F6Publishing: 49] [Article Influence: 4.5] [Reference Citation Analysis]
239 Hurley K, Reeves EP, Carroll TP, McElvaney NG. Tumor necrosis factor-α driven inflammation in alpha-1 antitrypsin deficiency: a new model of pathogenesis and treatment. Expert Rev Respir Med 2016;10:207-22. [PMID: 26634397 DOI: 10.1586/17476348.2016.1127759] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
240 Wei J, Rahman S, Ayaub EA, Dickhout JG, Ask K. Protein Misfolding and Endoplasmic Reticulum Stress in Chronic Lung Disease. Chest 2013;143:1098-105. [DOI: 10.1378/chest.12-2133] [Cited by in Crossref: 41] [Cited by in F6Publishing: 42] [Article Influence: 5.1] [Reference Citation Analysis]
241 Yoneyama T, Kasuya H, Akagawa H, Onda H, Nakajima T, Hori T, Inoue I, Lee J, Yang T, Kim C. Absence of Alpha-1 Antitrypsin Deficiency Alleles ( S and Z ) in Japanese and Korean Patients With Aneurysmal Subarachnoid Hemorrhage. Stroke 2004;35. [DOI: 10.1161/01.str.0000147966.81215.be] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
242 Patel D, Teckman JH. Alpha-1-Antitrypsin Deficiency Liver Disease. Clin Liver Dis. 2018;22:643-655. [PMID: 30266154 DOI: 10.1016/j.cld.2018.06.010] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 8.0] [Reference Citation Analysis]
243 Miravitlles M. [Emphysema due to alpha-1-antitrypsin deficiency: is it really an uncommon disease?]. Med Clin (Barc) 2004;123:778-9. [PMID: 15607070 DOI: 10.1016/s0025-7753(04)74666-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
244 Teckman JH, Rosenthal P, Abel R, Bass LM, Michail S, Murray KF, Rudnick DA, Thomas DW, Spino C, Arnon R, Hertel PM, Heubi J, Kamath BM, Karnsakul W, Loomes KM, Magee JC, Molleston JP, Romero R, Shneider BL, Sherker AH, Sokol RJ; Childhood Liver Disease Research Network (ChiLDReN). Baseline Analysis of a Young α-1-Antitrypsin Deficiency Liver Disease Cohort Reveals Frequent Portal Hypertension. J Pediatr Gastroenterol Nutr 2015;61:94-101. [PMID: 25651489 DOI: 10.1097/MPG.0000000000000753] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 2.8] [Reference Citation Analysis]
245 Yoshikura H. Epidemiological correlation between COVID-19 epidemic and prevalence of α-1 antitrypsin deficiency in the world. Glob Health Med 2021;3:73-81. [PMID: 33937569 DOI: 10.35772/ghm.2020.01068] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
246 Piitulainen E, Montero LC, Nystedt-Düzakin M, Stoel BC, Sveger T, Wollmer P, Tanash HA, Diaz S. Lung Function and CT Densitometry in Subjects with alpha-1-Antitrypsin Deficiency and Healthy Controls at 35 Years of Age. COPD 2015;12:162-7. [PMID: 25280185 DOI: 10.3109/15412555.2014.922068] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
247 Pemberton PA, Kobayashi D, Wilk BJ, Henstrand JM, Shapiro SD, Barr PJ. Inhaled recombinant alpha 1-antitrypsin ameliorates cigarette smoke-induced emphysema in the mouse. COPD 2006;3:101-8. [PMID: 17175673 DOI: 10.1080/15412550600651248] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 1.6] [Reference Citation Analysis]
248 Borna H, Hosseini Qale Noe SH, Harchegani AB, Talatappe NR, Ghatrehsamani M, Ghanei M, Shahriary A. A review on proteomics analysis to reveal biological pathways and predictive proteins in sulfur mustard exposed patients: roles of inflammation and oxidative stress. Inhalation Toxicology 2019;31:3-11. [DOI: 10.1080/08958378.2018.1558316] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
249 Pini L, Paoletti G, Heffler E, Tantucci C, Puggioni F; Asthma and Alpha1-Antitrypsin Research Group. Alpha1-antitrypsin deficiency and asthma. Curr Opin Allergy Clin Immunol 2021;21:46-51. [PMID: 33284159 DOI: 10.1097/ACI.0000000000000711] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
250 Stearns K, Goldklang M, Xiao R, Zelonina T, Blomenkamp K, Teckman J, D'Armiento JM. Knockdown of Alpha-1 Antitrypsin with antisense oligonucleotide does not exacerbate smoke induced lung injury. PLoS One 2021;16:e0246040. [PMID: 33539438 DOI: 10.1371/journal.pone.0246040] [Reference Citation Analysis]
251 Tarini BA, Burke W, Scott CR, Wilfond BS. Waiving informed consent in newborn screening research: balancing social value and respect. Am J Med Genet C Semin Med Genet 2008;148C:23-30. [PMID: 18200521 DOI: 10.1002/ajmg.c.30164] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
252 Pérez-Holanda S, Blanco I, Menéndez M, Rodrigo L. Serum concentration of alpha-1 antitrypsin is significantly higher in colorectal cancer patients than in healthy controls. BMC Cancer 2014;14:355. [PMID: 24886427 DOI: 10.1186/1471-2407-14-355] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 3.9] [Reference Citation Analysis]
253 Godoy I. Diagnosing alpha-1 antitrypsin deficiency: does it prevent or improve the course of COPD? J Bras Pneumol 2016;42:307-8. [PMID: 27812626 DOI: 10.1590/S1806-37562016000400002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
254 Cazzola M, Rogliani P, Ora J, Matera MG. Treatment options for moderate-to-very severe chronic obstructive pulmonary disease. Expert Opin Pharmacother 2016;17:977-88. [PMID: 26894516 DOI: 10.1517/14656566.2016.1155555] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
255 Al-Jameil N, Hassan AA, Hassanato R, Isac SR, Otaiby MA, Al-Shareef F, Al-Maarik B, Ajeyan IA, Al-Bahloul K, Ghani S, Al-Torbak D. The prevalence of PI*S and PI*Z SERPINA1 alleles in healthy individuals and COPD patients in Saudi Arabia: A case-control study. Medicine (Baltimore) 2017;96:e8320. [PMID: 29049242 DOI: 10.1097/MD.0000000000008320] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
256 Vidal Pla R, Padullés Zamora N, Sala Piñol F, Jardí Margalef R, Rodríguez Frías F, Bruno Montoro Ronsano J. Farmacocinética de la alfa-1-antitripsina utilizada en el tratamiento sustitutivo del enfisema congénito grave. Archivos de Bronconeumología 2006;42:553-6. [DOI: 10.1157/13093399] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
257 Mal H. BPCO : actualités diverses. Revue des Maladies Respiratoires 2004;21:44-8. [DOI: 10.1016/s0761-8425(04)71505-3] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
258 Sanders CL, Ponte A, Kueppers F. The Effects of Inflammation on Alpha 1 Antitrypsin Levels in a National Screening Cohort. COPD: Journal of Chronic Obstructive Pulmonary Disease 2018;15:10-6. [DOI: 10.1080/15412555.2017.1401600] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 9.0] [Reference Citation Analysis]
259 Dickens JA, Lomas DA. Why has it been so difficult to prove the efficacy of alpha-1-antitrypsin replacement therapy? Insights from the study of disease pathogenesis. Drug Des Devel Ther 2011;5:391-405. [PMID: 21966212 DOI: 10.2147/DDDT.S14018] [Cited by in Crossref: 5] [Cited by in F6Publishing: 17] [Article Influence: 0.5] [Reference Citation Analysis]
260 Sandström CS, Novoradovskaya N, Cilio CM, Piitulainen E, Sveger T, Janciauskiene S. Endotoxin receptor CD14 in PiZ alpha-1-antitrypsin deficiency individuals. Respir Res 2008;9:34. [PMID: 18426570 DOI: 10.1186/1465-9921-9-34] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
261 Russo AJ, Neville L, Wroge C. Low Serum Alpha-1 Antitrypsin (AAT) in Family Members of Individuals with Autism Correlates with PiMZ Genotype. Biomark Insights 2009;4:45-56. [PMID: 19652762 DOI: 10.4137/bmi.s1115] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
262 Bernhard N, Lepper PM, Vogelmeier C, Seibert M, Wagenpfeil S, Bals R, Fähndrich S. Intensive smoking diminishes the differences in quality of life and exacerbation frequency between the alpha-1-antitrypsin deficiency genotypes PiZZ and PiSZ. Respir Med 2017;130:1-8. [PMID: 29206626 DOI: 10.1016/j.rmed.2017.07.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
263 Balch WE, Sznajder JI, Budinger S, Finley D, Laposky AD, Cuervo AM, Benjamin IJ, Barreiro E, Morimoto RI, Postow L, Weissman AM, Gail D, Banks-Schlegel S, Croxton T, Gan W. Malfolded protein structure and proteostasis in lung diseases. Am J Respir Crit Care Med 2014;189:96-103. [PMID: 24033344 DOI: 10.1164/rccm.201306-1164WS] [Cited by in Crossref: 4] [Cited by in F6Publishing: 22] [Article Influence: 0.6] [Reference Citation Analysis]
264 Wienke S, Brown K, Farmer M, Strange C. Expanded carrier screening panels-does bigger mean better? J Community Genet 2014;5:191-8. [PMID: 24062228 DOI: 10.1007/s12687-013-0169-6] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 4.0] [Reference Citation Analysis]
265 Price DB, Yawn BP, Jones RC. Improving the differential diagnosis of chronic obstructive pulmonary disease in primary care. Mayo Clin Proc 2010;85:1122-9. [PMID: 21123639 DOI: 10.4065/mcp.2010.0389] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 2.7] [Reference Citation Analysis]
266 Blanco I, Lara B, de Serres F. Efficacy of alpha1-antitrypsin augmentation therapy in conditions other than pulmonary emphysema. Orphanet J Rare Dis 2011;6:14. [PMID: 21486454 DOI: 10.1186/1750-1172-6-14] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 3.7] [Reference Citation Analysis]
267 Stolk J. Alpha-1-antitrypsin augmentation treatment: does one size fit all? Thorax 2006;61:1034. [PMID: 17114371 DOI: 10.1136/thx.2006.067710] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
268 Campos MA, Lascano J. α1 Antitrypsin deficiency: current best practice in testing and augmentation therapy. Ther Adv Respir Dis 2014;8:150-61. [PMID: 25013223 DOI: 10.1177/1753465814542243] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
269 Spratt JR, Brown RZ, Rudser K, Goswami U, Hertz MI, Patil J, Cich I, Shumway SJ, Loor G. Greater survival despite increased complication rates following lung transplant for alpha-1-antitrypsin deficiency compared to chronic obstructive pulmonary disease. J Thorac Dis 2019;11:1130-44. [PMID: 31179055 DOI: 10.21037/jtd.2019.04.40] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
270 Wilkens M, Bartlett M, Willersinn F, O'Hara K, Boyd J, Denning J. The patient perspective of alpha-1 antitrypsin deficiency: disease burden and unmet needs. Breathe (Sheff) 2021;17:200340. [PMID: 34295404 DOI: 10.1183/20734735.0340-2020] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
271 Stoller JK, Aboussouan LS, Kanner RE, Wilson LA, Diaz P, Wise R; LOTT Research Group. Characteristics of Alpha-1 Antitrypsin-Deficient Individuals in the Long-term Oxygen Treatment Trial and Comparison with Other Subjects with Chronic Obstructive Pulmonary Disease. Ann Am Thorac Soc 2015;12:1796-804. [PMID: 26653189 DOI: 10.1513/AnnalsATS.201506-389OC] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
272 Vidal R, Blanco I, Casas F, Jardí R, Miratvilles M. Diagnóstico y tratamiento del déficit de alfa-1-antitripsina. Archivos de Bronconeumología 2006;42:645-59. [DOI: 10.1157/13095974] [Cited by in Crossref: 84] [Cited by in F6Publishing: 46] [Article Influence: 5.6] [Reference Citation Analysis]
273 Kaushal S, Annamali M, Blomenkamp K, Rudnick D, Halloran D, Brunt EM, Teckman JH. Rapamycin reduces intrahepatic alpha-1-antitrypsin mutant Z protein polymers and liver injury in a mouse model. Exp Biol Med (Maywood). 2010;235:700-709. [PMID: 20511674 DOI: 10.1258/ebm.2010.009297] [Cited by in Crossref: 81] [Cited by in F6Publishing: 72] [Article Influence: 7.4] [Reference Citation Analysis]
274 Chorostowska-wynimko J. Targeted screening programmes in COPD: how to identify individuals with α 1 -antitrypsin deficiency. Eur Respir Rev 2015;24:40-5. [DOI: 10.1183/09059180.00010614] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
275 Topic A, Stankovic M, Divac-Rankov A, Petrovic-Stanojevic N, Mitic-Milikic M, Nagorni-Obradovic L, Radojkovic D. Alpha-1-antitrypsin deficiency in Serbian adults with lung diseases. Genet Test Mol Biomarkers 2012;16:1282-6. [PMID: 22971141 DOI: 10.1089/gtmb.2012.0152] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
276 Esquinas C, Janciauskiene S, Gonzalo R, Mas de Xaxars G, Olejnicka B, Belmonte I, Barrecheguren M, Rodriguez E, Nuñez A, Rodriguez-Frias F, Miravitlles M. Gene and miRNA expression profiles in PBMCs from patients with severe and mild emphysema and PiZZ alpha1-antitrypsin deficiency. Int J Chron Obstruct Pulmon Dis 2017;12:3381-90. [PMID: 29238183 DOI: 10.2147/COPD.S145445] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
277 Strange C. Alpha-1 Antitrypsin Deficiency Associated COPD. Clinics in Chest Medicine 2020;41:339-45. [DOI: 10.1016/j.ccm.2020.05.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
278 Serapinas D, Sitkauskiene B, Sakalauskas R. Inflammatory markers in chronic obstructive pulmonary disease patients with different α1 antitrypsin genotypes. Arch Med Sci 2012;8:1053-8. [PMID: 23319981 DOI: 10.5114/aoms.2012.32414] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
279 Stolk J, Seersholm N, Kalsheker N. Alpha1-antitrypsin deficiency: current perspective on research, diagnosis, and management. Int J Chron Obstruct Pulmon Dis 2006;1:151-60. [PMID: 18046892 DOI: 10.2147/copd.2006.1.2.151] [Cited by in Crossref: 9] [Cited by in F6Publishing: 14] [Article Influence: 0.7] [Reference Citation Analysis]
280 Serrano-Mollar A. [Alveolar epithelial cell injury as an etiopathogenic factor in pulmonary fibrosis]. Arch Bronconeumol 2012;48 Suppl 2:2-6. [PMID: 23116901 DOI: 10.1016/S0300-2896(12)70044-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
281 Al-Jameil N, Hassan AA, Buhairan A, Hassanato R, Isac SR, Al-Otaiby M, Al-Maarik B, Al-Ajeyan I. Genotyping diagnosis of alpha-1 antitrypsin deficiency in Saudi adults with liver cirrhosis. Medicine (Baltimore) 2017;96:e6071. [PMID: 28178162 DOI: 10.1097/MD.0000000000006071] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
282 Chiuchiolo MJ, Crystal RG. Gene Therapy for Alpha-1 Antitrypsin Deficiency Lung Disease. Ann Am Thorac Soc 2016;13 Suppl 4:S352-69. [PMID: 27564673 DOI: 10.1513/AnnalsATS.201506-344KV] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
283 Chorostowska-Wynimko J, Barrecheguren M, Ferrarotti I, Greulich T, Sandhaus RA, Campos M. New Patient-Centric Approaches to the Management of Alpha-1 Antitrypsin Deficiency. Int J Chron Obstruct Pulmon Dis 2020;15:345-55. [PMID: 32103933 DOI: 10.2147/COPD.S234646] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
284 Quinn M, Ellis P, Pye A, Turner AM. Obstacles to Early Diagnosis and Treatment of Alpha-1 Antitrypsin Deficiency: Current Perspectives. Ther Clin Risk Manag 2020;16:1243-55. [PMID: 33364772 DOI: 10.2147/TCRM.S234377] [Reference Citation Analysis]
285 Hersh CP. Diagnosing alpha-1 antitrypsin deficiency: the first step in precision medicine. F1000Res 2017;6:2049. [PMID: 29225784 DOI: 10.12688/f1000research.12399.1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
286 Bals R, Koczulla R, Kotke V, Andress J, Blackert K, Vogelmeier C. Identification of individuals with alpha-1-antitrypsin deficiency by a targeted screening program. Respir Med 2007;101:1708-14. [PMID: 17428650 DOI: 10.1016/j.rmed.2007.02.024] [Cited by in Crossref: 48] [Cited by in F6Publishing: 42] [Article Influence: 3.4] [Reference Citation Analysis]
287 Spínola C, Bruges-armas J, Pereira C, Brehm A, Spínola H. Alpha-1-antitrypsin deficiency in Madeira (Portugal): The highest prevalence in the world. Respiratory Medicine 2009;103:1498-502. [DOI: 10.1016/j.rmed.2009.04.012] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
288 Miravitlles M, Soler-Cataluña JJ, Calle M, Molina J, Almagro P, Quintano JA, Riesco JA, Trigueros JA, Piñera P, Simón A, López-Campos JL, Soriano JB, Ancochea J. [Spanish COPD Guidelines (GesEPOC): Pharmacological treatment of stable COPD]. Aten Primaria 2012;44:425-37. [PMID: 22704760 DOI: 10.1016/j.aprim.2012.04.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
289 Wen JH, Wen H, Gibson-Corley KN, Glenn KA. FBG1 Is the Final Arbitrator of A1AT-Z Degradation. PLoS One 2015;10:e0135591. [PMID: 26295339 DOI: 10.1371/journal.pone.0135591] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
290 Teckman JH. Liver Disease in Alpha-1 Antitrypsin Deficiency: Current Understanding and Future Therapy. COPD: Journal of Chronic Obstructive Pulmonary Disease 2013;10:35-43. [DOI: 10.3109/15412555.2013.765839] [Cited by in Crossref: 51] [Cited by in F6Publishing: 37] [Article Influence: 6.4] [Reference Citation Analysis]
291 Rahaghi FF, Sandhaus RA, Brantly ML, Rouhani F, Campos MA, Strange C, Hogarth DK, Eden E, Stocks JM, Krowka MJ, Stoller JK. The prevalence of alpha-1 antitrypsin deficiency among patients found to have airflow obstruction. COPD 2012;9:352-8. [PMID: 22506682 DOI: 10.3109/15412555.2012.669433] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 3.1] [Reference Citation Analysis]
292 Vaz Rodrigues L, Costa F, Marques P, Mendonça C, Rocha J, Seixas S. Severe α-1 antitrypsin deficiency caused by Q0(Ourém) allele: clinical features, haplotype characterization and history. Clin Genet 2012;81:462-9. [PMID: 21457231 DOI: 10.1111/j.1399-0004.2011.01670.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
293 Donato LJ, Jenkins SM, Smith C, Katzmann JA, Snyder MR. Reference and interpretive ranges for α(1)-antitrypsin quantitation by phenotype in adult and pediatric populations. Am J Clin Pathol 2012;138:398-405. [PMID: 22912357 DOI: 10.1309/AJCPMEEJK32ACYFP] [Cited by in Crossref: 32] [Cited by in F6Publishing: 8] [Article Influence: 3.6] [Reference Citation Analysis]
294 Greulich T, Nell C, Herr C, Vogelmeier C, Kotke V, Wiedmann S, Wencker M, Bals R, Koczulla AR. Results from a large targeted screening program for alpha-1-antitrypsin deficiency: 2003 - 2015. Orphanet J Rare Dis 2016;11:75. [PMID: 27282198 DOI: 10.1186/s13023-016-0453-8] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
295 Lascano JE, Campos MA. The important role of primary care providers in the detection of alpha-1 antitrypsin deficiency. Postgrad Med 2017;129:889-95. [PMID: 28929906 DOI: 10.1080/00325481.2017.1381539] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
296 Veith M, Klemmer A, Anton I, El Hamss R, Rapun N, Janciauskiene S, Kotke V, Herr C, Bals R, Vogelmeier CF, Greulich T. Diagnosing Alpha-1-Antitrypsin Deficiency Using A PCR/Luminescence-Based Technology. Int J Chron Obstruct Pulmon Dis 2019;14:2535-42. [PMID: 31819391 DOI: 10.2147/COPD.S224221] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
297 Payne JG, Takahashi A, Higgins MI, Porter EL, Suki B, Balazs A, Wilson AA. Multilineage transduction of resident lung cells in vivo by AAV2/8 for α1-antitrypsin gene therapy. Mol Ther Methods Clin Dev 2016;3:16042. [PMID: 27408904 DOI: 10.1038/mtm.2016.42] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
298 Garcia Hejl C, Riviere F, Sill JM, Chianea D, Vest P. An unusual electrophoresis. Clin Chem 2014;60:1127-8. [PMID: 25070977 DOI: 10.1373/clinchem.2013.218842] [Reference Citation Analysis]
299 Michel T, Kankura A, Salinas Medina ML, Kurz J, Behring A, Avci-Adali M, Nolte A, Schlensak C, Wendel HP, Krajewski S. In Vitro Evaluation of a Novel mRNA-Based Therapeutic Strategy for the Treatment of Patients Suffering from Alpha-1-Antitrypsin Deficiency. Nucleic Acid Ther 2015;25:235-44. [PMID: 26125662 DOI: 10.1089/nat.2015.0537] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
300 Brantly ML, Lascano JE, Shahmohammadi A. Intravenous Alpha-1 Antitrypsin Therapy for Alpha-1 Antitrypsin Deficiency: The Current State of the Evidence. Chronic Obstr Pulm Dis 2018;6:100-14. [PMID: 30775428 DOI: 10.15326/jcopdf.6.1.2017.0185] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
301 Meinke L, Chitkara R, Krishna G. Advances in the management of chronic obstructive pulmonary disease. Expert Opin Pharmacother 2007;8:23-37. [PMID: 17163804 DOI: 10.1517/14656566.8.1.23] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
302 Sorrells S, Camprubi S, Griffin R, Chen J, Ayguasanosa J. SPARTA clinical trial design: exploring the efficacy and safety of two dose regimens of alpha1-proteinase inhibitor augmentation therapy in alpha1-antitrypsin deficiency. Respir Med 2015;109:490-9. [PMID: 25727857 DOI: 10.1016/j.rmed.2015.01.022] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.7] [Reference Citation Analysis]
303 Marszal E, Shrake A. Characterization of differences in isoelectric focusing behavior of alpha1-proteinase inhibitor products. Transfusion 2006;46:872-3. [DOI: 10.1111/j.1537-2995.2006.00809.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
304 Clark VC. Liver Transplantation in Alpha-1 Antitrypsin Deficiency. Clin Liver Dis 2017;21:355-65. [PMID: 28364818 DOI: 10.1016/j.cld.2016.12.008] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
305 Laffranchi M, Elliston ELK, Gangemi F, Berardelli R, Lomas DA, Irving JA, Fra A. Characterisation of a type II functionally-deficient variant of alpha-1-antitrypsin discovered in the general population. PLoS One 2019;14:e0206955. [PMID: 30633749 DOI: 10.1371/journal.pone.0206955] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
306 Teckman JH, Jain A. Advances in alpha-1-antitrypsin deficiency liver disease. Curr Gastroenterol Rep 2014;16:367. [PMID: 24338605 DOI: 10.1007/s11894-013-0367-8] [Cited by in Crossref: 29] [Cited by in F6Publishing: 21] [Article Influence: 4.1] [Reference Citation Analysis]
307 Greene DN, Elliott-jelf M, Straseski JA, Grenache DG. Facilitating the Laboratory Diagnosis of α1-Antitrypsin Deficiency. American Journal of Clinical Pathology 2013;139:184-91. [DOI: 10.1309/ajcp6xbk8ulzxwfp] [Cited by in Crossref: 23] [Cited by in F6Publishing: 3] [Article Influence: 2.9] [Reference Citation Analysis]
308 Denden S, Zorzetto M, Amri F, Knani J, Ottaviani S, Scabini R, Gorrini M, Ferrarotti I, Campo I, Chibani JB, Khelil AH, Luisetti M. Screening for Alpha 1 antitrypsin deficiency in Tunisian subjects with obstructive lung disease: a feasibility report. Orphanet J Rare Dis 2009;4:12. [PMID: 19368725 DOI: 10.1186/1750-1172-4-12] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
309 Carpenter MJ, Strange C, Jones Y, Dickson MR, Carter C, Moseley MA, Gilbert GE. Does genetic testing result in behavioral health change? Changes in smoking behavior following testing for alpha-1 antitrypsin deficiency. Ann Behav Med 2007;33:22-8. [PMID: 17291167 DOI: 10.1207/s15324796abm3301_3] [Cited by in Crossref: 52] [Cited by in F6Publishing: 45] [Article Influence: 3.7] [Reference Citation Analysis]
310 Perciaccante A, Negri C, Coralli A, Charlier P, Appenzeller O, Bianucci R. Was Ugo Foscolo (1778-1827) affected by alpha-1 antitrypsin deficiency? Med Hypotheses 2018;111:1-3. [PMID: 29406986 DOI: 10.1016/j.mehy.2017.12.014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
311 de Serres FJ, Blanco I, Fernández-bustillo E. Ethnic differences in alpha-1 antitrypsin deficiency in the United States of America. Ther Adv Respir Dis 2010;4:63-70. [DOI: 10.1177/1753465810365158] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 2.7] [Reference Citation Analysis]
312 Piccolo P, Annunziata P, Soria LR, Attanasio S, Barbato A, Castello R, Carissimo A, Quagliata L, Terracciano LM, Brunetti-Pierri N. Down-regulation of hepatocyte nuclear factor-4α and defective zonation in livers expressing mutant Z α1-antitrypsin. Hepatology 2017;66:124-35. [PMID: 28295475 DOI: 10.1002/hep.29160] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
313 Sorroche PB, Fernández Acquier M, López Jove O, Giugno E, Pace S, Livellara B, Legal S, Oyhamburu J, Saez MS. Déficit de alfa 1 antitripsina en pacientes con EPOC: estudio de corte transversal. Archivos de Bronconeumología 2015;51:539-43. [DOI: 10.1016/j.arbres.2015.01.008] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
314 Aboussouan LS, Stoller JK. Detection of alpha-1 antitrypsin deficiency: a review. Respir Med 2009;103:335-41. [PMID: 19013782 DOI: 10.1016/j.rmed.2008.10.006] [Cited by in Crossref: 40] [Cited by in F6Publishing: 32] [Article Influence: 3.1] [Reference Citation Analysis]
315 Tapper EB, Patwardhan VR, Curry M. Low yield and utilization of confirmatory testing in a cohort of patients with liver disease assessed for alpha-1 antitrypsin deficiency. Dig Dis Sci 2015;60:1589-94. [PMID: 25532504 DOI: 10.1007/s10620-014-3490-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
316 Laffranchi M, Elliston EL, Miranda E, Perez J, Ronzoni R, Jagger AM, Heyer-Chauhan N, Brantly ML, Fra A, Lomas DA, Irving JA. Intrahepatic heteropolymerization of M and Z alpha-1-antitrypsin. JCI Insight 2020;5:135459. [PMID: 32699193 DOI: 10.1172/jci.insight.135459] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
317 Hiller AM, Piitulainen E, Jehpsson L, Tanash H. Decline in FEV1 and hospitalized exacerbations in individuals with severe alpha-1 antitrypsin deficiency. Int J Chron Obstruct Pulmon Dis 2019;14:1075-83. [PMID: 31213789 DOI: 10.2147/COPD.S195847] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
318 Blanco I, de Serres FJ, Cárcaba V, Lara B, Fernández-Bustillo E. Alpha-1 Antitrypsin Deficiency PI*Z and PI*S Gene Frequency Distribution Using on Maps of the World by an Inverse Distance Weighting (IDW) Multivariate Interpolation Method. Hepat Mon 2012;12:e7434. [PMID: 23166537 DOI: 10.5812/hepatmon.7434] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 3.2] [Reference Citation Analysis]
319 Ekeowa U, Gooptu B, Belorgey D, Hägglöf P, Karlsson-li S, Miranda E, Pérez J, Macleod I, Kroger H, Marciniak S, Crowther D, Lomas D. α1-Antitrypsin deficiency, chronic obstructive pulmonary disease and the serpinopathies. Clinical Science 2009;116:837-50. [DOI: 10.1042/cs20080484] [Cited by in Crossref: 41] [Cited by in F6Publishing: 24] [Article Influence: 3.4] [Reference Citation Analysis]
320 Ruiz M, Lacaille F, Berthiller J, Joly P, Dumortier J, Aumar M, Bridoux‐henno L, Jacquemin E, Lamireau T, Broué P, Rivet C, Belmalih A, Restier L, Chapuis‐cellier C, Bouchecareilh M, Lachaux A, Tacke F; Groupe Francophone d’Hépatologie Gastroentérologie et Nutrition Pédiatriques. Liver disease related to alpha1‐antitrypsin deficiency in French children: The DEFI‐ALPHA cohort. Liver Int 2019;39:1136-46. [DOI: 10.1111/liv.14035] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 6.5] [Reference Citation Analysis]
321 Ljujic M, Topic A, Divac A, Nikolic A, Petrovic-stanojevic N, Surlan M, Mitic-milikic M, Radojkovic D. Isoelectric focusing phenotyping and denaturing gradient gel electrophoresis genotyping: a comparison of two methods in detection of alpha-1-antitrypsin variants. Translational Research 2008;151:255-9. [DOI: 10.1016/j.trsl.2008.02.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
322 Karadagi A, Johansson H, Zemack H, Salipalli S, Mörk LM, Kannisto K, Jorns C, Gramignoli R, Strom S, Stokkeland K, Ericzon BG, Jonigk D, Janciauskiene S, Nowak G, Ellis ECS. Exogenous alpha 1-antitrypsin down-regulates SERPINA1 expression. PLoS One 2017;12:e0177279. [PMID: 28486562 DOI: 10.1371/journal.pone.0177279] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
323 Nenke MA, Holmes M, Rankin W, Lewis JG, Torpy DJ. Corticosteroid-binding globulin cleavage is paradoxically reduced in alpha-1 antitrypsin deficiency: Implications for cortisol homeostasis. Clin Chim Acta 2016;452:27-31. [PMID: 26522656 DOI: 10.1016/j.cca.2015.10.028] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
324 Lara B, Miravitlles M. Spanish Registry of Patients With Alpha-1 Antitrypsin Deficiency; Comparison of the Characteristics of PISZ and PIZZ Individuals. COPD: Journal of Chronic Obstructive Pulmonary Disease 2015;12:27-31. [DOI: 10.3109/15412555.2015.1021912] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 3.7] [Reference Citation Analysis]
325 Kohn R, Margolis ML. Localized Pulmonary Densities in a Patient with α1-Antitrypsin Deficiency. Ann Am Thorac Soc 2015;12:940-4. [PMID: 26075555 DOI: 10.1513/AnnalsATS.201411-509CC] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
326 Pla RV, Zamora NP, Piñol FS, Margaleff RJ, Frias FR, Montoro Ronsano JB. Pharmacokinetics of α1-Antitrypsin Replacement Therapy in Severe Congenital Emphysema. Archivos de Bronconeumología ((English Edition)) 2006;42:553-6. [DOI: 10.1016/s1579-2129(06)60583-1] [Cited by in Crossref: 4] [Article Influence: 0.3] [Reference Citation Analysis]
327 Cottin V, Brillet P, Nunes H, Cordier J. Syndrome d'emphysème des sommets et fibrose pulmonaire des bases combinés. La Presse Médicale 2007;36:936-44. [DOI: 10.1016/j.lpm.2007.03.005] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
328 Wilson AA, Murphy GJ, Hamakawa H, Kwok LW, Srinivasan S, Hovav AH, Mulligan RC, Amar S, Suki B, Kotton DN. Amelioration of emphysema in mice through lentiviral transduction of long-lived pulmonary alveolar macrophages. J Clin Invest. 2010;120:379-389. [PMID: 20038801 DOI: 10.1172/JCI36666] [Cited by in Crossref: 51] [Cited by in F6Publishing: 33] [Article Influence: 4.3] [Reference Citation Analysis]
329 Foreman MG, Campos M, Celedón JC. Genes and chronic obstructive pulmonary disease. Med Clin North Am 2012;96:699-711. [PMID: 22793939 DOI: 10.1016/j.mcna.2012.02.006] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
330 Sosulski ML, Stiles KM, Frenk EZ, Hart FM, Matsumura Y, De BP, Kaminsky SM, Crystal RG. Gene therapy for alpha 1-antitrypsin deficiency with an oxidant-resistant human alpha 1-antitrypsin. JCI Insight 2020;5:135951. [PMID: 32759494 DOI: 10.1172/jci.insight.135951] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
331 Donahue JM, Cassivi SD. Lung Volume Reduction Surgery for Patients with Alpha-1 Antitrypsin Deficiency Emphysema. Thoracic Surgery Clinics 2009;19:201-8. [DOI: 10.1016/j.thorsurg.2009.02.002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
332 Teckman JH, Lindblad D. Alpha-1-antitrypsin deficiency: diagnosis, pathophysiology, and management. Curr Gastroenterol Rep 2006;8:14-20. [PMID: 16510030 DOI: 10.1007/s11894-006-0059-8] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
333 Kim WJ, Wood AM, Barker AF, Brantly ML, Campbell EJ, Eden E, McElvaney G, Rennard SI, Sandhaus RA, Stocks JM, Stoller JK, Strange C, Turino G, Silverman EK, Stockley RA, Demeo DL. Association of IREB2 and CHRNA3 polymorphisms with airflow obstruction in severe alpha-1 antitrypsin deficiency. Respir Res 2012;13:16. [PMID: 22356581 DOI: 10.1186/1465-9921-13-16] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 3.6] [Reference Citation Analysis]
334 Tortorici MA, Rogers JA, Vit O, Bexon M, Sandhaus RA, Burdon J, Chorostowska-Wynimko J, Thompson P, Stocks J, McElvaney NG, Chapman KR, Edelman JM. Quantitative disease progression model of α-1 proteinase inhibitor therapy on computed tomography lung density in patients with α-1 antitrypsin deficiency. Br J Clin Pharmacol 2017;83:2386-97. [PMID: 28662542 DOI: 10.1111/bcp.13358] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
335 Schouten IGM, Kasteleyn MJ, Tsonaka R, Bals R, Turner AC, Ferrarotti I, Corsico AG, Lara B, Miravitlles M, Stockley RA, Stolk J. Long-term effect of α1-antitrypsin augmentation therapy on the decline of FEV1 in deficient patients: an analysis of the AIR database. ERJ Open Res 2021;7:00194-2021. [PMID: 34435030 DOI: 10.1183/23120541.00194-2021] [Reference Citation Analysis]
336 Tonelli AR, Brantly ML. Augmentation therapy in alpha-1 antitrypsin deficiency: advances and controversies. Ther Adv Respir Dis 2010;4:289-312. [DOI: 10.1177/1753465810373911] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 2.6] [Reference Citation Analysis]
337 Stocks JM, Brantly ML, Wang-Smith L, Campos MA, Chapman KR, Kueppers F, Sandhaus RA, Strange C, Turino G. Pharmacokinetic comparability of Prolastin®-C to Prolastin® in alpha₁-antitrypsin deficiency: a randomized study. BMC Clin Pharmacol 2010;10:13. [PMID: 20920295 DOI: 10.1186/1472-6904-10-13] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.1] [Reference Citation Analysis]
338 Connolly B, Isaacs C, Cheng L, Asrani KH, Subramanian RR. SERPINA1 mRNA as a Treatment for Alpha-1 Antitrypsin Deficiency. J Nucleic Acids 2018;2018:8247935. [PMID: 30009048 DOI: 10.1155/2018/8247935] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
339 Bidla G, Rosenblatt DS, Gilfix BM. Identification of Variants in Alpha-1-Antitrypsin by High Resolution Melting. J Appl Lab Med 2021;6:715-28. [PMID: 33331634 DOI: 10.1093/jalm/jfaa191] [Reference Citation Analysis]
340 Tonelli AR, Rouhani F, Li N, Schreck P, Brantly ML. Alpha-1-antitrypsin augmentation therapy in deficient individuals enrolled in the Alpha-1 Foundation DNA and Tissue Bank. Int J Chron Obstruct Pulmon Dis 2009;4:443-52. [PMID: 20054436 DOI: 10.2147/copd.s8577] [Cited by in Crossref: 33] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
341 Kaserman JE, Hurley K, Dodge M, Villacorta-Martin C, Vedaie M, Jean JC, Liberti DC, James MF, Higgins MI, Lee NJ, Washko GR, San Jose Estepar R, Teckman J, Kotton DN, Wilson AA. A Highly Phenotyped Open Access Repository of Alpha-1 Antitrypsin Deficiency Pluripotent Stem Cells. Stem Cell Reports 2020;15:242-55. [PMID: 32619491 DOI: 10.1016/j.stemcr.2020.06.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
342 Modrykamien A, Stoller JK. Alpha-1 antitrypsin (AAT) deficiency - what are the treatment options? Expert Opin Pharmacother 2009;10:2653-61. [PMID: 19827990 DOI: 10.1517/14656560903300111] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
343 Charro N, Hood BL, Faria D, Pacheco P, Azevedo P, Lopes C, de Almeida AB, Couto FM, Conrads TP, Penque D. Serum proteomics signature of cystic fibrosis patients: a complementary 2-DE and LC-MS/MS approach. J Proteomics 2011;74:110-26. [PMID: 20950718 DOI: 10.1016/j.jprot.2010.10.001] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 2.2] [Reference Citation Analysis]
344 Topic AS, Jelic-Ivanovic ZD, Spasojevic-Kalimanovska VV, Spasic SM. Association of moderate alpha-1 antitrypsin deficiency with lung cancer in the Serbian population. Arch Med Res. 2006;37:866-870. [PMID: 16971227 DOI: 10.1016/j.arcmed.2006.05.006] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
345 Pastore N, Blomenkamp K, Annunziata F, Piccolo P, Mithbaokar P, Maria Sepe R, Vetrini F, Palmer D, Ng P, Polishchuk E, Iacobacci S, Polishchuk R, Teckman J, Ballabio A, Brunetti-Pierri N. Gene transfer of master autophagy regulator TFEB results in clearance of toxic protein and correction of hepatic disease in alpha-1-anti-trypsin deficiency. EMBO Mol Med. 2013;5:397-412. [PMID: 23381957 DOI: 10.1002/emmm.201202046] [Cited by in Crossref: 100] [Cited by in F6Publishing: 90] [Article Influence: 12.5] [Reference Citation Analysis]
346 Ioachimescu OC, Stoller JK. A Review of Alpha-1 Antitrypsin Deficiency. COPD: Journal of Chronic Obstructive Pulmonary Disease 2009;2:263-75. [DOI: 10.1081/copd-57602] [Cited by in Crossref: 23] [Article Influence: 1.9] [Reference Citation Analysis]
347 Rachelefsky G, Hogarth DK. Issues in the diagnosis of alpha 1-antitrypsin deficiency. J Allergy Clin Immunol 2008;121:833-8. [PMID: 18313128 DOI: 10.1016/j.jaci.2007.12.1183] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
348 Lyon MJ. Metabolic panniculitis: alpha-1 antitrypsin deficiency panniculitis and pancreatic panniculitis. Dermatol Ther. 2010;23:368-374. [PMID: 20666824 DOI: 10.1111/j.1529-8019.2010.01337.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
349 Wood AM, Stockley RA. Alpha one antitrypsin deficiency: from gene to treatment. Respiration 2007;74:481-92. [PMID: 17671403 DOI: 10.1159/000105536] [Cited by in Crossref: 50] [Cited by in F6Publishing: 40] [Article Influence: 3.6] [Reference Citation Analysis]
350 Janciauskiene SM, Bals R, Koczulla R, Vogelmeier C, Köhnlein T, Welte T. The discovery of α1-antitrypsin and its role in health and disease. Respir Med 2011;105:1129-39. [PMID: 21367592 DOI: 10.1016/j.rmed.2011.02.002] [Cited by in Crossref: 179] [Cited by in F6Publishing: 163] [Article Influence: 17.9] [Reference Citation Analysis]
351 Campos MA, Alazemi S, Zhang G, Salathe M, Wanner A, Sandhaus RA, Baier H. Clinical characteristics of subjects with symptoms of alpha1-antitrypsin deficiency older than 60 years. Chest 2009;135:600-8. [PMID: 19017884 DOI: 10.1378/chest.08-1129] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 1.6] [Reference Citation Analysis]
352 Brebner JA, Stockley RA. Recent advances in α-1-antitrypsin deficiency-related lung disease. Expert Review of Respiratory Medicine 2014;7:213-30. [DOI: 10.1586/ers.13.20] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 4.0] [Reference Citation Analysis]
353 Kaczor MP, Sanak M, Szczeklik A. Rapid and inexpensive detection of alpha1-antitrypsin deficiency-related alleles S and Z by a real-time polymerase chain reaction suitable for a large-scale population-based screening. J Mol Diagn 2007;9:99-104. [PMID: 17251342 DOI: 10.2353/jmoldx.2007.060048] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
354 Mostafavi B, Diaz S, Tanash HA, Piitulainen E. Liver function in alpha-1-antitrypsin deficient individuals at 37 to 40 years of age. Medicine (Baltimore) 2017;96:e6180. [PMID: 28328804 DOI: 10.1097/MD.0000000000006180] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
355 Hogarth DK, Rachelefsky G. Screening and familial testing of patients for alpha 1-antitrypsin deficiency. Chest 2008;133:981-8. [PMID: 18398118 DOI: 10.1378/chest.07-1001] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 2.4] [Reference Citation Analysis]
356 Stockley RA. Alpha-1 Antitrypsin Deficiency: Phenotypes and Quality of Life. Ann Am Thorac Soc 2016;13 Suppl 4:S332-5. [PMID: 27564669 DOI: 10.1513/AnnalsATS.201507-436KV] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
357 Bruse S, Moreau M, Bromberg Y, Jang JH, Wang N, Ha H, Picchi M, Lin Y, Langley RJ, Qualls C, Klensney-Tait J, Zabner J, Leng S, Mao J, Belinsky SA, Xing J, Nyunoya T. Whole exome sequencing identifies novel candidate genes that modify chronic obstructive pulmonary disease susceptibility. Hum Genomics 2016;10:1. [PMID: 26744305 DOI: 10.1186/s40246-015-0058-7] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
358 Craig TJ. Suspecting and Testing for Alpha-1 Antitrypsin Deficiency-An Allergist's and/or Immunologist's Perspective. J Allergy Clin Immunol Pract 2015;3:506-11. [PMID: 26032475 DOI: 10.1016/j.jaip.2015.04.005] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
359 Molloy K, Hersh CP, Morris VB, Carroll TP, O'Connor CA, Lasky-Su JA, Greene CM, O'Neill SJ, Silverman EK, McElvaney NG. Clarification of the risk of chronic obstructive pulmonary disease in α1-antitrypsin deficiency PiMZ heterozygotes. Am J Respir Crit Care Med 2014;189:419-27. [PMID: 24428606 DOI: 10.1164/rccm.201311-1984OC] [Cited by in Crossref: 104] [Cited by in F6Publishing: 48] [Article Influence: 14.9] [Reference Citation Analysis]
360 Barrecheguren M, Monteagudo M, Simonet P, Llor C, Rodriguez E, Ferrer J, Esquinas C, Miravitlles M. Diagnosis of alpha-1 antitrypsin deficiency: a population-based study. Int J Chron Obstruct Pulmon Dis 2016;11:999-1004. [PMID: 27274221 DOI: 10.2147/COPD.S108505] [Cited by in Crossref: 2] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
361 Wozniak J, Wandtke T, Kopinski P, Chorostowska-Wynimko J. Challenges and Prospects for Alpha-1 Antitrypsin Deficiency Gene Therapy. Hum Gene Ther 2015;26:709-18. [PMID: 26413996 DOI: 10.1089/hum.2015.044] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
362 Cortes-Lopez R, Barjaktarevic I. Alpha-1 Antitrypsin Deficiency: a Rare Disease? Curr Allergy Asthma Rep 2020;20:51. [PMID: 32572624 DOI: 10.1007/s11882-020-00942-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
363 Teckman JH, Mangalat N. Alpha-1 antitrypsin and liver disease: mechanisms of injury and novel interventions. Expert Rev Gastroenterol Hepatol. 2015;9:261-268. [PMID: 25066184 DOI: 10.1586/17474124.2014.943187] [Cited by in Crossref: 32] [Cited by in F6Publishing: 23] [Article Influence: 4.6] [Reference Citation Analysis]
364 Sandhaus RA, Stocks J, Rouhani FN, Brantly M, Strauss P. Biochemical efficacy and safety of a new, ready-to-use, liquid alpha-1-proteinase inhibitor, GLASSIA (alpha1-proteinase inhibitor (human), intravenous). COPD 2014;11:17-25. [PMID: 23822603 DOI: 10.3109/15412555.2013.804500] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
365 Mahr AD, Edberg JC, Stone JH, Hoffman GS, St Clair EW, Specks U, Dellaripa PF, Seo P, Spiera RF, Rouhani FN, Brantly ML, Merkel PA. Alpha₁-antitrypsin deficiency-related alleles Z and S and the risk of Wegener's granulomatosis. Arthritis Rheum 2010;62:3760-7. [PMID: 20827781 DOI: 10.1002/art.27742] [Cited by in Crossref: 64] [Cited by in F6Publishing: 47] [Article Influence: 6.4] [Reference Citation Analysis]
366 Zillmer LR, Russo R, Manzano BM, Ivanaga I, Nascimento OA, Souza AA, Santos G Jr, Rodriguez F, Miravitlles M, Jardim JR. Validation and development of an immunonephelometric assay for the determination of alpha-1 antitrypsin levels in dried blood spots from patients with COPD. J Bras Pneumol 2013;39:547-54. [PMID: 24310627 DOI: 10.1590/S1806-37132013000500004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
367 Gooptu B, Dickens JA, Lomas DA. The molecular and cellular pathology of α₁-antitrypsin deficiency. Trends Mol Med 2014;20:116-27. [PMID: 24374162 DOI: 10.1016/j.molmed.2013.10.007] [Cited by in Crossref: 76] [Cited by in F6Publishing: 67] [Article Influence: 9.5] [Reference Citation Analysis]
368 Remih K, Amzou S, Strnad P. Alpha1-antitrypsin deficiency: New therapies on the horizon. Curr Opin Pharmacol 2021;59:149-56. [PMID: 34256305 DOI: 10.1016/j.coph.2021.06.001] [Reference Citation Analysis]
369 Regev A, Guaqueta C, Molina EG, Conrad A, Mishra V, Brantly ML, Torres M, De Medina M, Tzakis AG, Schiff ER. Does the heterozygous state of alpha-1 antitrypsin deficiency have a role in chronic liver diseases? Interim results of a large case-control study. J Pediatr Gastroenterol Nutr 2006;43 Suppl 1:S30-5. [PMID: 16819398 DOI: 10.1097/01.mpg.0000226387.56612.1e] [Cited by in Crossref: 43] [Cited by in F6Publishing: 34] [Article Influence: 3.1] [Reference Citation Analysis]
370 Hernández Pérez JM, Fumero García S, Alvarez Pío A. Successful α1-antitrypsin replacement therapy in a patient with α1-antitrypsin deficiency and granulomatosis with polyangiitis. Rheumatology (Oxford) 2013;52:755-7. [PMID: 22923761 DOI: 10.1093/rheumatology/kes233] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
371 Piitulainen E, Tanash HA. The Clinical Profile of Subjects Included in the Swedish National Register on Individuals with Severe Alpha 1-Antitrypsin deficiency. COPD: Journal of Chronic Obstructive Pulmonary Disease 2015;12:36-41. [DOI: 10.3109/15412555.2015.1021909] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
372 Russo R, Zillmer LR, Nascimento OA, Manzano B, Ivanaga IT, Fritscher L, Lundgren F, Miravitlles M, Gondim HD, Santos G Junior, Alves MA, Oliveira MV, Souza AA, Sales MP, Jardim JR. Prevalence of alpha-1 antitrypsin deficiency and allele frequency in patients with COPD in Brazil. J Bras Pneumol 2016;42:311-6. [PMID: 27812629 DOI: 10.1590/S1806-37562015000000180] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
373 Hogan PE, Koelsch T, Daley CL, Kasperbauer SH. A Woman with a 15-Year History of Bronchiectasis and Recurrent Nontuberculous Mycobacterium Pulmonary Disease. Ann Am Thorac Soc 2018;15:380-2. [PMID: 29493335 DOI: 10.1513/AnnalsATS.201707-585CC] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
374 Casas F, Blanco I, Martínez MT, Bustamante A, Miravitlles M, Cadenas S, Hernández JM, Lázaro L, Rodríguez E, Rodríguez-frías F, Torres M, Lara B. Indications for Active Case Searches and Intravenous Alpha-1 Antitrypsin Treatment for Patients With Alpha-1 Antitrypsin Deficiency Chronic Pulmonary Obstructive Disease: An Update. Archivos de Bronconeumología (English Edition) 2015;51:185-92. [DOI: 10.1016/j.arbr.2014.12.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
375 Sandhaus RA, Turino G, Brantly ML, Campos M, Cross CE, Goodman K, Hogarth DK, Knight SL, Stocks JM, Stoller JK, Strange C, Teckman J. The Diagnosis and Management of Alpha-1 Antitrypsin Deficiency in the Adult. Chronic Obstr Pulm Dis 2016;3:668-82. [PMID: 28848891 DOI: 10.15326/jcopdf.3.3.2015.0182] [Cited by in Crossref: 40] [Cited by in F6Publishing: 55] [Article Influence: 8.0] [Reference Citation Analysis]
376 Ferrarotti I, Scabini R, Campo I, Ottaviani S, Zorzetto M, Gorrini M, Luisetti M. Laboratory diagnosis of alpha1-antitrypsin deficiency. Translational Research 2007;150:267-74. [DOI: 10.1016/j.trsl.2007.08.001] [Cited by in Crossref: 62] [Cited by in F6Publishing: 57] [Article Influence: 4.4] [Reference Citation Analysis]
377 Ferreira TCDS, Queiroz MAF, Argañaraz GA, Ishak R, Vallinoto ACR, Argañaraz ER. A1AT polymorphisms may be associated with clinical characteristics of retrovirus infections in a mixed ethnic population from the Brazilian Amazon region. Int J Infect Dis 2017;65:67-71. [PMID: 29030134 DOI: 10.1016/j.ijid.2017.10.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
378 Chu JH, Zang W, Vukmirovic M, Yan X, Adams T, DeIuliis G, Hu B, Mihaljinec A, Schupp JC, Becich MJ, Hochheiser H, Gibson KF, Chen ES, Morris A, Leader JK, Wisniewski SR, Zhang Y, Sciurba FC, Collman RG, Sandhaus R, Herzog EL, Patterson KC, Sauler M, Strange C, Kaminski N; GRADS Investigators. Gene coexpression networks reveal novel molecular endotypes in alpha-1 antitrypsin deficiency. Thorax 2021;76:134-43. [PMID: 33303696 DOI: 10.1136/thoraxjnl-2019-214301] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
379 de la Roza C, Lara B, Vilà S, Miravitlles M. [Alpha1-antitrypsin deficiency: situation in Spain and development of a screening program]. Arch Bronconeumol 2006;42:290-8. [PMID: 16827978 DOI: 10.1016/s1579-2129(06)60145-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
380 Campos MA, Wanner A. The Rationale for Pharmacologic Therapy in Stable Chronic Obstructive Pulmonary Disease. The American Journal of the Medical Sciences 2005;329:181-9. [DOI: 10.1097/00000441-200504000-00004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
381 Heresi GA, Stoller JK. Augmentation therapy in alpha-1 antitrypsin deficiency. Expert Opin Biol Ther 2008;8:515-26. [PMID: 18352854 DOI: 10.1517/14712598.8.4.515] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
382 Hatipoğlu U, Stoller JK. α1-Antitrypsin Deficiency. Clin Chest Med 2016;37:487-504. [PMID: 27514595 DOI: 10.1016/j.ccm.2016.04.011] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
383 Torres-Durán M, Lopez-Campos JL, Barrecheguren M, Miravitlles M, Martinez-Delgado B, Castillo S, Escribano A, Baloira A, Navarro-Garcia MM, Pellicer D, Bañuls L, Magallón M, Casas F, Dasí F. Alpha-1 antitrypsin deficiency: outstanding questions and future directions. Orphanet J Rare Dis 2018;13:114. [PMID: 29996870 DOI: 10.1186/s13023-018-0856-9] [Cited by in Crossref: 47] [Cited by in F6Publishing: 26] [Article Influence: 15.7] [Reference Citation Analysis]
384 Thabut G, Mornex J, Cuvelier A, Padrazzi B, Pison C, Neukirch F, Lafitte J, Boczkowski J, Balduyck M, Muir J, Carles P, Fournier M. Caractéristiques des patients inclus dans la cohorte française de patients emphysémateux déficitaires en alpha-1 antitrypsine. Revue des Maladies Respiratoires 2008;25:1115-22. [DOI: 10.1016/s0761-8425(08)74982-9] [Cited by in Crossref: 6] [Article Influence: 0.5] [Reference Citation Analysis]
385 Foreman MG, Wilson C, DeMeo DL, Hersh CP, Beaty TH, Cho MH, Ziniti J, Curran-Everett D, Criner G, Hokanson JE, Brantly M, Rouhani FN, Sandhaus RA, Crapo JD, Silverman EK; Genetic Epidemiology of COPD (COPDGene) Investigators * . Alpha-1 Antitrypsin PiMZ Genotype Is Associated with Chronic Obstructive Pulmonary Disease in Two Racial Groups. Ann Am Thorac Soc 2017;14:1280-7. [PMID: 28380308 DOI: 10.1513/AnnalsATS.201611-838OC] [Cited by in Crossref: 32] [Cited by in F6Publishing: 18] [Article Influence: 10.7] [Reference Citation Analysis]
386 Tuohy MM, Remund KF, Hilfiker R, Murphy DT, Murray JG, Egan JJ. Endobronchial valve deployment in severe α-1 antitrypsin deficiency emphysema: a case series: Emphysema, endobronchial valve treatment. The Clinical Respiratory Journal 2013;7:45-52. [DOI: 10.1111/j.1752-699x.2012.00280.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 2] [Article Influence: 1.4] [Reference Citation Analysis]
387 Luna Diaz LV, Iupe I, Zavala B, Balestrini KC, Guerrero A, Holt G, Calderon-Candelario R, Mirsaeidi M, Campos M. Improving adherence to alpha-1 antitrypsin deficiency screening guidelines using the pulmonary function laboratory. Int J Chron Obstruct Pulmon Dis 2017;12:2257-9. [PMID: 28814853 DOI: 10.2147/COPD.S143424] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
388 Zhumagaliyeva A, Ottaviani S, Greulich T, Gorrini M, Vogelmeier C, Karazhanova L, Nurgazina G, DeSilvestri A, Kotke V, Barzon V, Zorzetto M, Corsico A, Ferrarotti I. Case-finding for alpha1-antitrypsin deficiency in Kazakh patients with COPD. Multidiscip Respir Med 2017;12:23. [PMID: 29090095 DOI: 10.1186/s40248-017-0104-5] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
389 Qin L, Luo G, Zhang J, Xu N. A novel method of detecting alpha-1 antitrypsin deficiency of Z mutant (GAG342AAG) in a single PCR reaction using base-quenched probe. Clinica Chimica Acta 2014;427:29-33. [DOI: 10.1016/j.cca.2013.09.042] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
390 Thabut G. Cohorte nationale de patients emphysémateux déficitaires en alpha-1 antitrypsine. Revue des Maladies Respiratoires 2005;22:1053-7. [DOI: 10.1016/s0761-8425(05)85738-9] [Cited by in Crossref: 7] [Article Influence: 0.4] [Reference Citation Analysis]
391 Snyder MR, Katzmann JA, Butz ML, Yang P, Dawson DB, Halling KC, Highsmith WE, Thibodeau SN. Diagnosis of α-1-Antitrypsin Deficiency: An Algorithm of Quantification, Genotyping, and Phenotyping. Clinical Chemistry 2006;52:2236-42. [DOI: 10.1373/clinchem.2006.072991] [Cited by in Crossref: 77] [Cited by in F6Publishing: 55] [Article Influence: 5.1] [Reference Citation Analysis]
392 Nelson DR, Teckman J, Di Bisceglie AM, Brenner DA. Diagnosis and management of patients with α1-antitrypsin (A1AT) deficiency. Clin Gastroenterol Hepatol 2012;10:575-80. [PMID: 22200689 DOI: 10.1016/j.cgh.2011.12.028] [Cited by in Crossref: 46] [Cited by in F6Publishing: 40] [Article Influence: 4.6] [Reference Citation Analysis]
393 Felisbino MB, Fernandes FLA, Nucci MCNM, Pinto RMC, Pizzichini E, Cukier A. The patient profile of individuals with Alpha-1 antitrypsine gene mutations at a referral center in Brazil. J Bras Pneumol 2018;44:383-9. [PMID: 30517339 DOI: 10.1590/S1806-37562017000000420] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
394 Zhan SH, Abboud RT, Jung B, Kuchinka B, Ralston D, Casey B, Mattman A. Sanger sequencing solved a cryptic case of severe alpha1-antitrypsin deficiency. Clinical Biochemistry 2012;45:499-501. [DOI: 10.1016/j.clinbiochem.2012.01.027] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
395 Lara B. EPOC y déficit de alfa-1-antitripsina. Archivos de Bronconeumología 2010;46:2-8. [DOI: 10.1016/s0300-2896(10)70026-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 2] [Article Influence: 1.1] [Reference Citation Analysis]
396 Hanania NA, Sharafkhaneh A. Update on the pharmacologic therapy for chronic obstructive pulmonary disease. Clin Chest Med 2007;28:589-607, vi-vii. [PMID: 17720046 DOI: 10.1016/j.ccm.2007.06.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
397 Morer L, Choudat L, Dauriat G, Durand F, Cazals-hatem D, Thabut G, Brugière O, Castier Y, Mal H. Liver Involvement in Patients With PiZZ-Emphysema, Candidates for Lung Transplantation. Am J Transplant 2017;17:1389-95. [DOI: 10.1111/ajt.14152] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
398 Gaebel K, McIvor RA, Xie F, Blackhouse G, Robertson D, Assasi N, Hernandez P, Goeree R. Triple therapy for the management of COPD: a review. COPD 2011;8:206-43. [PMID: 21513437 DOI: 10.3109/15412555.2011.560131] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
399 Huber F, Schmid-scherzer K, Wantke F, Frantal S, Kneussl M. Alpha1-Antitrypsin-Mangel in Österreich: Auswertung der österreichischen Datenbank des internationalen Alpha1-Antitrypsin Registers. Wien Klin Wochenschr 2010;122:390-6. [DOI: 10.1007/s00508-010-1399-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
400 Miskoff JA, Khan B, Chaudhri M, Phan H, Carson MP. Identifying Alpha-1 Antitrypsin Deficiency Based on Computed Tomography Evidence of Emphysema. Cureus 2019;11:e3971. [PMID: 30956923 DOI: 10.7759/cureus.3971] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
401 Struniawski R, Szpechcinski A, Poplawska B, Skronski M, Chorostowska-wynimko J. Rapid DNA Extraction Protocol for Detection of Alpha-1 Antitrypsin Deficiency from Dried Blood Spots by Real-Time PCR. In: Pokorski M, editor. Respiratory Regulation - The Molecular Approach. Dordrecht: Springer Netherlands; 2013. pp. 29-37. [DOI: 10.1007/978-94-007-4549-0_5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
402 Fregonese L, Stolk J, Frants RR, Veldhuisen B. Alpha-1 antitrypsin Null mutations and severity of emphysema. Respiratory Medicine 2008;102:876-84. [DOI: 10.1016/j.rmed.2008.01.009] [Cited by in Crossref: 65] [Cited by in F6Publishing: 54] [Article Influence: 5.0] [Reference Citation Analysis]
403 Greulich T, Chlumsky J, Wencker M, Vit O, Fries M, Chung T, Shebl A, Vogelmeier C, Chapman KR, McElvaney NG; RAPID Trial Group. Safety of biweekly α1-antitrypsin treatment in the RAPID programme. Eur Respir J 2018;52:1800897. [PMID: 30237305 DOI: 10.1183/13993003.00897-2018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
404 Santos G, Turner AM. Alpha-1 antitrypsin deficiency: an update on clinical aspects of diagnosis and management. Fac Rev 2020;9:1. [PMID: 33659933 DOI: 10.12703/b/9-1] [Reference Citation Analysis]
405 Blanco I, Bueno P, Diego I, Pérez-Holanda S, Lara B, Casas-Maldonado F, Esquinas C, Miravitlles M. Alpha-1 antitrypsin Pi*SZ genotype: estimated prevalence and number of SZ subjects worldwide. Int J Chron Obstruct Pulmon Dis 2017;12:1683-94. [PMID: 28652721 DOI: 10.2147/COPD.S137852] [Cited by in Crossref: 37] [Cited by in F6Publishing: 16] [Article Influence: 9.3] [Reference Citation Analysis]
406 Köhnlein T, Welte T. Alpha-1 Antitrypsin Deficiency: Pathogenesis, Clinical Presentation, Diagnosis, and Treatment. The American Journal of Medicine 2008;121:3-9. [DOI: 10.1016/j.amjmed.2007.07.025] [Cited by in Crossref: 78] [Cited by in F6Publishing: 53] [Article Influence: 6.0] [Reference Citation Analysis]
407 Nolte JL, Ataya A, Merrill H, Childs M, Brantly M. Alpha1-antitrypsin Deficiency-Increased Knowledge and Diagnostic Testing after Viewing Short Instructional Video. COPD 2017;14:52-5. [PMID: 27819491 DOI: 10.1080/15412555.2016.1245280] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
408 Sandhaus RA, Strange C, Zanichelli A, Skålvoll K, Koczulla AR, Stockley RA. Improving the Lives of Patients with Alpha-1 Antitrypsin Deficiency. Int J Chron Obstruct Pulmon Dis 2020;15:3313-22. [PMID: 33328731 DOI: 10.2147/COPD.S276773] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
409 Cummings EE, O'Reilly LP, King DE, Silverman RM, Miedel MT, Luke CJ, Perlmutter DH, Silverman GA, Pak SC. Deficient and Null Variants of SERPINA1 Are Proteotoxic in a Caenorhabditis elegans Model of α1-Antitrypsin Deficiency. PLoS One 2015;10:e0141542. [PMID: 26512890 DOI: 10.1371/journal.pone.0141542] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
410 Brunt EM, Blomenkamp K, Ahmed M, Ali F, Marcus N, Teckman J. Hepatic progenitor cell proliferation and liver injury in α-1-antitrypsin deficiency. J Pediatr Gastroenterol Nutr 2010;51:626-30. [PMID: 20890217 DOI: 10.1097/MPG.0b013e3181e7ff55] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
411 de Serres F, Blanco I. Role of alpha-1 antitrypsin in human health and disease. J Intern Med 2014;276:311-35. [PMID: 24661570 DOI: 10.1111/joim.12239] [Cited by in Crossref: 108] [Cited by in F6Publishing: 92] [Article Influence: 15.4] [Reference Citation Analysis]
412 Segeritz CP, Rashid ST, de Brito MC, Serra MP, Ordonez A, Morell CM, Kaserman JE, Madrigal P, Hannan NRF, Gatto L, Tan L, Wilson AA, Lilley K, Marciniak SJ, Gooptu B, Lomas DA, Vallier L. hiPSC hepatocyte model demonstrates the role of unfolded protein response and inflammatory networks in α1-antitrypsin deficiency. J Hepatol 2018;69:851-60. [PMID: 29879455 DOI: 10.1016/j.jhep.2018.05.028] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 5.7] [Reference Citation Analysis]
413 Ottaviani S, Barzon V, Buxens A, Gorrini M, Larruskain A, El Hamss R, Balderacchi AM, Corsico AG, Ferrarotti I. Molecular diagnosis of alpha1-antitrypsin deficiency: A new method based on Luminex technology. J Clin Lab Anal 2020;34:e23279. [PMID: 32181528 DOI: 10.1002/jcla.23279] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
414 Blanco I, Janciauskiene S, Nita I, Fernández-Bustillo E, Cárcaba V, Gallo C, Alvarez-Rico M, de Serres F, Béridze N. Low plasma levels of monocyte chemoattractant protein-1 (MCP-1), tumor necrosis factor-alpha (TNFalpha), and vascular endothelial growth factor (VEGF) in patients with alpha1-antitrypsin deficiency-related fibromyalgia. Clin Rheumatol 2010;29:189-97. [PMID: 19924498 DOI: 10.1007/s10067-009-1318-5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
415 American Pharmacists Association Foundation. White paper on expanding the role of pharmacists in chronic obstructive pulmonary disease: American Pharmacists Association Foundation. J Am Pharm Assoc (2003) 2011;51:203-11. [PMID: 21382811 DOI: 10.1331/JAPhA.2011.11513] [Cited by in Crossref: 17] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
416 Piitulainen E, Carlson J, Ohlsson K, Sveger T. Alpha1-antitrypsin deficiency in 26-year-old subjects: lung, liver, and protease/protease inhibitor studies. Chest 2005;128:2076-81. [PMID: 16236857 DOI: 10.1378/chest.128.4.2076] [Cited by in Crossref: 63] [Cited by in F6Publishing: 46] [Article Influence: 3.9] [Reference Citation Analysis]
417 Barjaktarevic I, Miravitlles M. Alpha-1 antitrypsin (AAT) augmentation therapy in individuals with the PI*MZ genotype: a pro/con debate on a working hypothesis. BMC Pulm Med 2021;21:99. [PMID: 33757485 DOI: 10.1186/s12890-021-01466-x] [Reference Citation Analysis]
418 Fromer L. Improving diagnosis and management of alpha-1 antitrypsin deficiency in primary care: translating knowledge into action. COPD 2010;7:192-8. [PMID: 20486818 DOI: 10.3109/15412555.2010.482577] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
419 Mohanka M, Khemasuwan D, Stoller JK. A review of augmentation therapy for alpha-1 antitrypsin deficiency. Expert Opin Biol Ther 2012;12:685-700. [PMID: 22500781 DOI: 10.1517/14712598.2012.676638] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
420 Menga G, Fernandez Acquier M, Echazarreta AL, Sorroche PB, Lorenzon MV, Fernández ME, Saez MS; grupo de estudio DAAT.AR. Prevalence of Alpha-1 Antitrypsin Deficiency in COPD Patients in Argentina. The DAAT.AR Study. Arch Bronconeumol (Engl Ed) 2020;56:571-7. [PMID: 31889566 DOI: 10.1016/j.arbres.2019.11.010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
421 Gaeckle NT, Stephenson L, Reilkoff RA. Alpha-1 Antitrypsin Deficiency and Pregnancy. COPD 2020;17:326-32. [PMID: 32308050 DOI: 10.1080/15412555.2020.1754778] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
422 Greulich T, Nell C, Hohmann D, Grebe M, Janciauskiene S, Koczulla AR, Vogelmeier CF. The prevalence of diagnosed α1-antitrypsin deficiency and its comorbidities: results from a large population-based database. Eur Respir J 2017;49:1600154. [PMID: 27824593 DOI: 10.1183/13993003.00154-2016] [Cited by in Crossref: 39] [Cited by in F6Publishing: 30] [Article Influence: 9.8] [Reference Citation Analysis]
423 Tacke F, Trautwein C. Controlling autophagy: a new concept for clearing liver disease. Hepatology. 2011;53:356-358. [PMID: 21254183 DOI: 10.1002/hep.24090] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
424 Drummond MB, Buist AS, Crapo JD, Wise RA, Rennard SI. Chronic obstructive pulmonary disease: NHLBI Workshop on the Primary Prevention of Chronic Lung Diseases. Ann Am Thorac Soc 2014;11 Suppl 3:S154-60. [PMID: 24754824 DOI: 10.1513/AnnalsATS.201312-432LD] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
425 Blanco I. Oxidant-mediated Aggregation of Z α 1 -Antitrypsin in Pulmonary Epithelial Cells Amplifies Lung Inflammation. Am J Respir Crit Care Med 2014;189:877-9. [DOI: 10.1164/rccm.201403-0402ed] [Cited by in Crossref: 3] [Article Influence: 0.4] [Reference Citation Analysis]
426 Rahaghi FF, Miravitlles M. Long-term clinical outcomes following treatment with alpha 1-proteinase inhibitor for COPD associated with alpha-1 antitrypsin deficiency: a look at the evidence. Respir Res 2017;18:105. [PMID: 28558837 DOI: 10.1186/s12931-017-0574-1] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
427 Sandhaus R, Strange C, Stone G, Runken MC, Blanchette CM, Howden R. Comorbidity Associations with AATD Among Commercially Insured and Medicare Beneficiaries with COPD in the US. Int J Chron Obstruct Pulmon Dis 2020;15:2389-97. [PMID: 33116454 DOI: 10.2147/COPD.S263297] [Reference Citation Analysis]
428 Jain A, McCarthy K, Xu M, Stoller JK. Impact of a clinical decision support system in an electronic health record to enhance detection of α₁-antitrypsin deficiency. Chest 2011;140:198-204. [PMID: 21193532 DOI: 10.1378/chest.10-1658] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
429 Baranovski BM, Schuster R, Nisim O, Brami I, Lior Y, Lewis EC. Alpha-1 Antitrypsin Substitution for Extrapulmonary Conditions in Alpha-1 Antitrypsin Deficient Patients. Chronic Obstr Pulm Dis 2018;5:267-76. [PMID: 30723784 DOI: 10.15326/jcopdf.5.4.2017.0161] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
430 de la Roza C, Lara B, Vilà S, Miravitlles M. Déficit de alfa-1-antitripsina. Situación en España y desarrollo de un programa de detección de casos. Archivos de Bronconeumología 2006;42:290-8. [DOI: 10.1157/13089541] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
431 Kelly E, Greene CM, Carroll TP, McElvaney NG, O’Neill SJ. Alpha-1 antitrypsin deficiency. Respir Med. 2010;104:763-772. [PMID: 20303723 DOI: 10.1016/j.rmed.2010.01.016] [Cited by in Crossref: 47] [Cited by in F6Publishing: 37] [Article Influence: 4.3] [Reference Citation Analysis]
432 Matamala N, Lara B, Gomez-Mariano G, Martínez S, Retana D, Fernandez T, Silvestre RA, Belmonte I, Rodriguez-Frias F, Vilar M, Sáez R, Iturbe I, Castillo S, Molina-Molina M, Texido A, Tirado-Conde G, Lopez-Campos JL, Posada M, Blanco I, Janciauskiene S, Martinez-Delgado B. Characterization of Novel Missense Variants of SERPINA1 Gene Causing Alpha-1 Antitrypsin Deficiency. Am J Respir Cell Mol Biol 2018;58:706-16. [PMID: 29232161 DOI: 10.1165/rcmb.2017-0179OC] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 6.5] [Reference Citation Analysis]
433 Tanash HA, Riise GC, Ekström MP, Hansson L, Piitulainen E. Survival benefit of lung transplantation for chronic obstructive pulmonary disease in Sweden. Ann Thorac Surg 2014;98:1930-5. [PMID: 25443001 DOI: 10.1016/j.athoracsur.2014.07.030] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
434 Pérez-rubio G, Jiménez-valverde LO, Ramírez-venegas A, Camarena Á, Sansores RH, Flores-trujillo F, Reséndiz-hernández JM, Falfán-valencia R. Prevalence of Alpha-1 Antitrypsin High-risk Variants in Mexican Mestizo Population and Their Association With Lung Function Values. Archivos de Bronconeumología (English Edition) 2015;51:80-5. [DOI: 10.1016/j.arbr.2014.11.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
435 Topic A, Alempijevic T, Milutinovic AS, Kovacevic N. Alpha-1-antitrypsin phenotypes in adult liver disease patients. Ups J Med Sci. 2009;114:228-234. [PMID: 19961268 DOI: 10.3109/03009730903243472] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
436 Santambrogio L, Tarsia P, Mendogni P, Tosi D. Transplant options for end stage chronic obstructive pulmonary disease in the context of multidisciplinary treatments. J Thorac Dis 2018;10:S3356-65. [PMID: 30450242 DOI: 10.21037/jtd.2018.04.166] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
437 Zamora M. Surgery for patients with Alpha 1 Antitrypsin Deficiency: A review. The American Journal of Surgery 2019;218:639-47. [DOI: 10.1016/j.amjsurg.2018.10.019] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
438 Parr DG, Lara B. Clinical utility of alpha-1 proteinase inhibitor in the management of adult patients with severe alpha-1 antitrypsin deficiency: a review of the current literature. Drug Des Devel Ther 2017;11:2149-62. [PMID: 28769553 DOI: 10.2147/DDDT.S105207] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
439 Horváth I, Canotilho M, Chlumský J, Chorostowska-Wynimko J, Corda L, Derom E, Ficker JH, Kneussl M, Miravitlles M, Sucena M, Thabut G, Turner AM, van 't Wout E, McElvaney NG. Diagnosis and management of α1-antitrypsin deficiency in Europe: an expert survey. ERJ Open Res 2019;5:00171-2018. [PMID: 30863774 DOI: 10.1183/23120541.00171-2018] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
440 Carey EJ, Iyer VN, Nelson DR, Nguyen JH, Krowka MJ. Outcomes for recipients of liver transplantation for alpha-1-antitrypsin deficiency-related cirrhosis: LT for AAT Deficiency-Related Cirrhosis. Liver Transpl 2013;19:1370-6. [DOI: 10.1002/lt.23744] [Cited by in Crossref: 43] [Cited by in F6Publishing: 26] [Article Influence: 5.4] [Reference Citation Analysis]
441 Turner AM. Alpha-1 antitrypsin deficiency: new developments in augmentation and other therapies. BioDrugs 2013;27:547-58. [PMID: 23771682 DOI: 10.1007/s40259-013-0042-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
442 Benzaquen J, Pradelli J, Padovani B, Marquette CH, Leroy S. [Emphysema, did you say emphysema?]. Rev Mal Respir 2018;35:83-7. [PMID: 29402641 DOI: 10.1016/j.rmr.2017.10.003] [Reference Citation Analysis]
443 Guilemany JM, Mullol J, Picado C. [Relation between rhinosinusitis and bronchiectasis]. Arch Bronconeumol 2006;42:135-40. [PMID: 16545252 DOI: 10.1016/s1579-2129(06)60132-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
444 Franciosi AN, Ralph J, O'Farrell NJ, Buckley C, Gulmann C, O'Kane M, Carroll TP, McElvaney NG. Alpha-1 antitrypsin deficiency-associated panniculitis. J Am Acad Dermatol 2021:S0190-9622(21)00232-2. [PMID: 33516773 DOI: 10.1016/j.jaad.2021.01.074] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
445 Tobin MJ. Chronic Obstructive Pulmonary Disease, Pollution, Pulmonary Vascular Disease, Transplantation, Pleural Disease, and Lung Cancer in AJRCCM 2003. Am J Respir Crit Care Med 2004;169:301-13. [DOI: 10.1164/rccm.2312007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
446 McCarthy C, Orr C, Fee LT, Carroll TP, Dunlea DM, Hunt DJL, Dunne E, O'Connell P, McCarthy G, Kenny D, Fearon U, Veale DJ, Reeves EP, McElvaney NG. Brief Report: Genetic Variation of the α1 -Antitrypsin Gene Is Associated With Increased Autoantibody Production in Rheumatoid Arthritis. Arthritis Rheumatol 2017;69:1576-9. [PMID: 28409899 DOI: 10.1002/art.40127] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
447 Clark VC, Marek G, Liu C, Collinsworth A, Shuster J, Kurtz T, Nolte J, Brantly M. Clinical and histologic features of adults with alpha-1 antitrypsin deficiency in a non-cirrhotic cohort. Journal of Hepatology 2018;69:1357-64. [DOI: 10.1016/j.jhep.2018.08.005] [Cited by in Crossref: 45] [Cited by in F6Publishing: 36] [Article Influence: 15.0] [Reference Citation Analysis]
448 Sorroche PB, Fernández Acquier M, López Jove O, Giugno E, Pace S, Livellara B, Legal S, Oyhamburu J, Saez MS. Alpha-1 Antitrypsin Deficiency in COPD Patients: A Cross-Sectional Study. Archivos de Bronconeumología (English Edition) 2015;51:539-43. [DOI: 10.1016/j.arbr.2015.09.013] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
449 Hishiya A, Koya K. Artificial DnaJ Protein for protein production and conformational diseases. Sci Rep 2017;7:8531. [PMID: 28819167 DOI: 10.1038/s41598-017-09067-7] [Reference Citation Analysis]
450 Bals R. Alpha-1-antitrypsin deficiency. Best Pract Res Clin Gastroenterol 2010;24:629-33. [PMID: 20955965 DOI: 10.1016/j.bpg.2010.08.006] [Cited by in Crossref: 36] [Cited by in F6Publishing: 28] [Article Influence: 3.6] [Reference Citation Analysis]
451 Herth FJF, Sandhaus RA, Turner AM, Sucena M, Welte T, Greulich T. Alpha 1 Antitrypsin Therapy in Patients with Alpha 1 Antitrypsin Deficiency: Perspectives from a Registry Study and Practical Considerations for Self-Administration During the COVID-19 Pandemic. Int J Chron Obstruct Pulmon Dis 2021;16:2983-96. [PMID: 34754184 DOI: 10.2147/COPD.S325211] [Reference Citation Analysis]
452 Perrin J, Aimone-gastin I, Balduyck M, Mercy M, Filhine-trésarrieu P, Odou M, Chaouat A, Chabot F. Déficit en alpha-1 antitrypsine secondaire à une mutation Null. Revue des Maladies Respiratoires 2016;33:612-7. [DOI: 10.1016/j.rmr.2015.10.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
453 Kaczor MP, Sanak M, Libura-Twardowska M, Szczeklik A. The prevalence of alpha(1)-antitrypsin deficiency in a representative population sample from Poland. Respir Med 2007;101:2520-5. [PMID: 17693072 DOI: 10.1016/j.rmed.2007.06.032] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
454 Yamashiro T, Matsuoka S, Estépar RS, Diaz A, Newell JD, Sandhaus RA, Mergo PJ, Brantly ML, Murayama S, Reilly JJ, Hatabu H, Silverman EK, Washko GR. Quantitative airway assessment on computed tomography in patients with alpha1-antitrypsin deficiency. COPD 2009;6:468-77. [PMID: 19938971 DOI: 10.3109/15412550903341521] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
455 Giacopuzzi E, Laffranchi M, Berardelli R, Ravasio V, Ferrarotti I, Gooptu B, Borsani G, Fra A. Real-world clinical applicability of pathogenicity predictors assessed on SERPINA1 mutations in alpha-1-antitrypsin deficiency. Human Mutation 2018;39:1203-13. [DOI: 10.1002/humu.23562] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
456 Zorzetto M, Ferrarotti I, Campo I, Balestrino A, Nava S, Gorrini M, Scabini R, Mazzola P, Luisetti M. Identification of a Novel Alpha1-Antitrypsin Null Variant (Q0Cairo): . Diagnostic Molecular Pathology 2005;14:121-4. [DOI: 10.1097/01.pas.0000155023.74859.d6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
457 Smith RA, Bishop RE. Insights into stigma management communication theory: Considering stigmatization as interpersonal influence. J Appl Commun Res 2019;47:571-90. [PMID: 33012878 DOI: 10.1080/00909882.2019.1675894] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
458 Behrens MA, Sendall TJ, Pedersen JS, Kjeldgaard M, Huntington JA, Jensen JK. The shapes of Z-α1-antitrypsin polymers in solution support the C-terminal domain-swap mechanism of polymerization. Biophys J 2014;107:1905-12. [PMID: 25418171 DOI: 10.1016/j.bpj.2014.08.030] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
459 Serra HG, Bertuzzo CS, Pereira MC, Rossi CL, Pinto Júnior W, Paschoal IA. Avaliação da concentração de alfa 1-antitripsina e da presença dos alelos S e Z em uma população de indivíduos sintomáticos respiratórios crônicos. J bras pneumol 2008;34:1019-25. [DOI: 10.1590/s1806-37132008001200006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
460 Stockley RA, Parr DG, Piitulainen E, Stolk J, Stoel BC, Dirksen A. Therapeutic efficacy of α-1 antitrypsin augmentation therapy on the loss of lung tissue: an integrated analysis of 2 randomised clinical trials using computed tomography densitometry. Respir Res. 2010;11:136. [PMID: 20920370 DOI: 10.1186/1465-9921-11-136] [Cited by in Crossref: 114] [Cited by in F6Publishing: 103] [Article Influence: 10.4] [Reference Citation Analysis]
461 Suárez-Lorenzo I, de Castro FR, Cruz-Niesvaara D, Herrera-Ramos E, Rodríguez-Gallego C, Carrillo-Diaz T. Alpha 1 antitrypsin distribution in an allergic asthmatic population sensitized to house dust mites. Clin Transl Allergy 2018;8:44. [PMID: 30410723 DOI: 10.1186/s13601-018-0231-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
462 Hawkins P, Sya J, Hup NK, Murphy MP, McElvaney NG, Reeves EP. Alpha-1 Antitrypsin Augmentation Inhibits Proteolysis of Neutrophil Membrane Voltage-Gated Proton Channel-1 in Alpha-1 Deficient Individuals. Medicina (Kaunas) 2021;57:814. [PMID: 34441020 DOI: 10.3390/medicina57080814] [Reference Citation Analysis]
463 Blanco I, Diego I, Bueno P, Pérez-holanda S, Casas-maldonado F, Miravitlles M. Prevalence of α 1 -antitrypsin PiZZ genotypes in patients with COPD in Europe: a systematic review. Eur Respir Rev 2020;29:200014. [DOI: 10.1183/16000617.0014-2020] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
464 Campos MA, Wanner A, Zhang G, Sandhaus RA. Trends in the diagnosis of symptomatic patients with alpha1-antitrypsin deficiency between 1968 and 2003. Chest 2005;128:1179-86. [PMID: 16162704 DOI: 10.1378/chest.128.3.1179] [Cited by in Crossref: 96] [Cited by in F6Publishing: 76] [Article Influence: 6.0] [Reference Citation Analysis]
465 Giovannoni MP, Schepetkin IA, Quinn MT, Cantini N, Crocetti L, Guerrini G, Iacovone A, Paoli P, Rossi P, Bartolucci G, Menicatti M, Vergelli C. Synthesis, biological evaluation, and molecular modelling studies of potent human neutrophil elastase (HNE) inhibitors. J Enzyme Inhib Med Chem 2018;33:1108-24. [PMID: 29969929 DOI: 10.1080/14756366.2018.1480615] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 4.7] [Reference Citation Analysis]
466 Pemberton PA, Cantwell JS, Kim KM, Sundin DJ, Kobayashi D, Fink JB, Shapiro SD, Barr PJ. An inhaled matrix metalloprotease inhibitor prevents cigarette smoke-induced emphysema in the mouse. COPD 2005;2:303-10. [PMID: 17146995 DOI: 10.1080/15412550500218171] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 1.7] [Reference Citation Analysis]
467 Abboud RT, Nelson TN, Jung B, Mattman A. Alpha1-antitrypsin deficiency: a clinical-genetic overview. Appl Clin Genet 2011;4:55-65. [PMID: 23776367 DOI: 10.2147/TACG.S10604] [Cited by in Crossref: 19] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
468 Saltini C, Krotova K. Mechanisms of lung disease in AATD. In: Strnad P, Brantly ML, Bals R, editors. α 1 -Antitrypsin Deficiency. Sheffield: European Respiratory Society; 2019. pp. 52-63. [DOI: 10.1183/2312508x.10032518] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
469 Green CE, Vayalapra S, Hampson JA, Mukherjee D, Stockley RA, Turner AM. PiSZ alpha-1 antitrypsin deficiency (AATD): pulmonary phenotype and prognosis relative to PiZZ AATD and PiMM COPD. Thorax 2015;70:939-45. [DOI: 10.1136/thoraxjnl-2015-206906] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 6.0] [Reference Citation Analysis]
470 Siri D, Farah H, Hogarth DK. Distinguishing alpha1-antitrypsin deficiency from asthma. Ann Allergy Asthma Immunol 2013;111:458-64. [PMID: 24267358 DOI: 10.1016/j.anai.2013.09.019] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
471 Bernspång E, Diaz S, Stoel B, Wollmer P, Sveger T, Piitulainen E. CT lung densitometry in young adults with alpha-1-antitrypsin deficiency. Respir Med 2011;105:74-9. [PMID: 20674322 DOI: 10.1016/j.rmed.2010.06.016] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
472 Franciosi AN, Carroll TP, McElvaney NG. Pitfalls and caveats in α1-antitrypsin deficiency testing: a guide for clinicians. Lancet Respir Med 2019;7:1059-67. [PMID: 31324540 DOI: 10.1016/S2213-2600(19)30141-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 4.5] [Reference Citation Analysis]
473 Ngan DA, Vickerman SV, Granville DJ, Man SF, Sin DD. The possible role of granzyme B in the pathogenesis of chronic obstructive pulmonary disease. Ther Adv Respir Dis 2009;3:113-29. [PMID: 19638369 DOI: 10.1177/1753465809341965] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
474 Fairbanks KD, Tavill AS. Liver disease in alpha 1-antitrypsin deficiency: a review. Am J Gastroenterol. 2008;103:2136-2141; quiz 2142. [PMID: 18796107 DOI: 10.1111/j.1572-0241.2008.01955.x] [Cited by in Crossref: 152] [Cited by in F6Publishing: 96] [Article Influence: 11.7] [Reference Citation Analysis]
475 Laffranchi M, Berardelli R, Ronzoni R, Lomas DA, Fra A. Heteropolymerization of α-1-antitrypsin mutants in cell models mimicking heterozygosity. Hum Mol Genet 2018;27:1785-93. [PMID: 29538751 DOI: 10.1093/hmg/ddy090] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
476 Fuchs SI, Schwerk N, Pittschieler K, Ahrens F, Baden W, Bals R, Fähndrich S, Gleiber W, Griese M, Hülskamp G, Köhnlein T, Reckling L, Rietschel E, Staab D, Gappa M. Lung clearance index for monitoring early lung disease in alpha-1-antitrypsin deficiency. Respir Med 2016;116:93-9. [PMID: 27296827 DOI: 10.1016/j.rmed.2016.04.015] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
477 Kim RG, Nguyen P, Bettencourt R, Dulai PS, Haufe W, Hooker J, Minocha J, Valasek MA, Aryafar H, Brenner DA, Sirlin CB, Loomba R. Magnetic resonance elastography identifies fibrosis in adults with alpha-1 antitrypsin deficiency liver disease: a prospective study. Aliment Pharmacol Ther 2016;44:287-99. [PMID: 27279429 DOI: 10.1111/apt.13691] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 4.6] [Reference Citation Analysis]
478 Tirado-conde G, Lara B, Miravitlles M. Augmentation therapy for emphysema due to alpha-1-antitrypsin deficiency. Ther Adv Respir Dis 2008;2:13-21. [DOI: 10.1177/1753465807088159] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]